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To maintain the readability of this dissertation, the use of abbreviations was 
minimized. Those that are used are found below: 
AER – Albumin excretion rate 
AGE – Advanced glycosylated end products  
AP – Alkaline phosphatase 
APC – Antigen presenting cells 
BMI – Body mass index  
CRP – C-reactive protein 
eGFR – Estimated glomerular filtration rate  
ESRD – End stage renal disease 
HDL – High density lipoprotein 
IBD – Inflammatory bowel disease 
ICAM – Intercellular adhesion molecule 
IFN (α&γ) – Interferon α&γ 
IL – Interleukin 
LAL – Limulus amebocyte lysate 
LADA – Latent autoimmune diabetes in adults 
LPS – Lipopolysaccharide  
MBL – Mannose-binding lectin 
mDC – Myeloid dendritic cell 
MetS – Metabolic syndrome 
MODY – Maturity onset diabetes of the young 
NF-kB – Nuclear factor kB 
PAMP – Pathogen- associated molecular pattern 
PRR – Pattern recognition receptor 
RTPCR – Reverse transcription polymerase chain reaction 
SCFA – Short chain fatty acid 
T1D – Type 1 Diabetes 
 
T2D – Type 2 diabetes 
TLR – Toll-like receptor 
TNF – Tumor necrosis factor 
WHO – World Health Organization 































List of Original Publications 
This thesis is based on the following publications, which are referred to in the text by 
their Roman numerals (I-III): 
 
I. Peräneva, L., Fogarty, C. L., Pussinen, P. J., Forsblom, C., Groop, P. H., & Lehto, M. 
Systemic exposure to Pseudomonal bacteria: a potential link between type 1 
diabetes and chronic inflammation. Acta Diabetologica (2013) 50:351-361. 
II. Fogarty, C. L., Nieminen, J. K., Peräneva, L., Lassenius, M. I., Taskinen, M.-R., 
Jauhiainen, M., Kirveskari, J., Pussinen, P., Hörkkö, S., Mäkinen, V.-P., Gordin, D., 
Forsblom, C., Groop, P.-H., Vaarala, O., and Lehto, M. High fat meal induces 
systemic cytokine release without evidence of endotoxemia-mediated cytokine 
production from circulating monocytes and myeloid dendritic cells. Acta 
Diabetologica (2015) 52(2):315-22. 
III. Lassenius, M.I.*, Fogarty, C. L.*, Blaut, M., Haimila, K., Riittinen, L., Paju, A., 
Kirveskari, J., Järvelä, J., Ahola, A. J., Gordin, D., Kumar, A., Hamarneh, S. R., Hodin, 
R., Sorsa, T., Tervahartiala, T., Hörkkö, S., Pussinen, P., Forsblom, C., Jauhiainen, 
M., Taskinen, M-R., Groop, P.-H., Lehto, M. on behalf of the FinnDiane Study. 
Intestinal alkaline phosphatase at the crossroad of intestinal health and disease: a 





I. Participated in data analysis and interpretation and the writing of the manuscript. 
Performed a significant portion of the DNA isolation, PCR amplification, cloning and 
sequencing work, downstream data processing and BLAST searches, and the RT-PCR 
quantification of bacterial DNA. 
 
II. Participated in the study design, data analysis and interpretation and manuscript 
writing. Performed the flow cytometry experiments and analysis as well as the 
cytokine multiplex experiments.  
 
III. Participated in study design, data analysis and interpretation and manuscript 
writing.  




















Publications not included in this thesis 
 
 
1. Duennwald, T., Bernardi, L., Gordin, D., Sandelin, A., Syreeni, A., Fogarty, C., 
Kytö JP, Gatterer H, Lehto M, Hörkkö S, Forsblom C, Burtscher M, Groop, P. H. 
Effects of a Single Bout of Interval Hypoxia on Cardio-Respiratory Control in 
Patients with Type 1 Diabetes Mellitus. Diabetes (2013) 62:4220-4227. 
 
2. Lassenius, M.I., Mäkinen, V.-P., Fogarty, C. L., Peräneva, L., Jauhiainen, M., 
Pussinen, P.J., Taskinen, M.-R., Kirveskari, J., Vaarala, O.,  Nieminen, J.K., 
Hörkkö, S., Kangas, A.J., Soininen, P., Ala-Korpela, M., Gordin, D., Ahola, A.J., 
Forsblom, C., Groop, P.-H., Lehto, M. Patients with type 1 diabetes show signs 
of vascular dysfunction in response to multiple high-fat meals. Nutr Metab 
(Lond). (2014) 11:28. 
 
3. Saurus, P., Kuusela, S., Lehtonen, E., Hyvönen, M. E., Ristola, M., Fogarty, C. L., 
Tienari, J., Lassenius, M. I., Forsblom, C., Lehto, M., Saleem, M.A., Groop, P-H., 
Holthöfer, H., Lehtonen S. Podocyte apoptosis is prevented by blocking the 
Toll-like receptor pathway. Cell Death and Disease (2015) May 7;6:e1752. 
 
4. Haapaniemi, E. M., Fogarty, C. L., Keskitalo, S., Takayama, S., Ilander, M., 
Krjutshkov, K., Vihinen, H., Jokitalo, E., Mustjoki, S., Lehto, M., Hautala, T., 
Varjosalo, M., Velagapudi, V., Seppänen, M., Kere, J. Combined 
immunodeficiency with hypoglycemia caused by mutations in hypoxia up-
regulated 1. The Journal of Allergy and Clinical Immunology (2016). 
 
5. Chen, W., Roslund, K., Fogarty, C.L., Pussinen, P., Halonen, L., Lehto, M., 
Groop, P.H., Metsälä, M., Lehto, M. Detection of hydrogen cyanide from the 
oral pathogen Porphyromonas gingivalis by cavity ring down spectroscopy. 
Scientific Reports (2016) March 4;6:22577. 
 
6. Saurus, P., Dumont, V., Kuusela, S., Lehtonen, E., Fogarty, C. L., Lassenius, M. 
I., Forsblom, C., Lehto, M., Saleem, M. A., Groop, P.-H., Holthöfer, H., and 
Lehtonen, S. CDK2 protects podocytes from apoptosis and is downregulated in 
podocyte injury. Scientific Reports (2016) Feb 15;6:21664. 
 
7. Wasik, A. A., Dumont, V., Tienari, J., Nyman, T. A., Fogarty, C. L., Forsblom, C., 
Lehto, M., Groop, P-H., and Lehtonen, S. Septin 7 and nonmuscle myosin IIA 
compete for binding to the SNARE complex to regulate glucose uptake into 
podocytes. Experimental Cell Research (2017) 350(2):336-348. 
 
8. Kaustio, M., Haapaniemi, E., Nurkkala, H., Park G., Syrjänen, J., Einarsdottir, E., 
Sahu, B., Kilpinen, S., Rounioja, S., Fogarty, C.L., Glumoff, V., Kulmala, P., 
Katayama, S., Tamene, F., Trotta, L., Morgunova, E., Krjutskov, K., Anssi, L., 
Martelius, T., Helminen, M., Mustjoki, S., Taipale, J., Saarela, J., Kere, J., 
Varjosalo, M., and Seppänen, M. Damaging heterozygous mutations in NFKB1 





















Type 1 diabetes (T1D) is a disease characterized by the autoimmune destruction of 
insulin-producing pancreatic β cells. Diabetic nephropathy is a life-threatening 
complication of T1D, characterized by the progressive loss of kidney function. 
Approximately one-third of all patients with T1D develop diabetic nephropathy. 
Bacterial DNA and bacterial lipopolysaccharides (LPS) are two categories of bacterial 
remnants that are known to induce inflammation. Inflammation and elevated levels 
of bacterial remnants have previously been shown to be associated with the 
development of diabetic nephropathy, and there is evidence in mice that these factors 
play a causal role in disease progression.  
The general aim of this thesis is to identify biological factors that modulate bacterial 
remnant-mediated inflammation in patients with T1D. Specifically, we aimed to better 
understand the composition, origin and consequences of bacterial remnants in 
circulation in the context of T1D by (1) evaluating the presence of bacterial DNA in the 
sera of patients with T1D and controls (Study I) and (2) measuring LPS activity, 
inflammation, inflammatory potential and gut-related factors in the context of 
multiple high-fat meals given to patients with T1D and healthy controls (Studies II & 
III).  
Study I found a higher frequency of Pseudomonal (Pa) DNA in circulation as well as 
elevated anti-Pa IgA levels in patients with T1D. These Pa-specific IgA antibodies 
correlated with higher C-reactive protein, a marker for inflammation, suggesting that 
patients with T1D undergo recurrent or chronic Pseudomonal exposure and 
potentially explaining the chronic inflammation in patients with T1D.  
Contrary to our hypotheses, study I found no correlation between LPS activity and 
either bacterial DNA composition or antibodies against identified bacterial species. 
This may be attributable to differences in the half-lives and host clearance 
mechanisms of bacterial remnants. However, it is also possible that the entry 
mechanisms and points of entry for LPS and bacterial DNA are different.  
 
The identification of numerous bacteria known to be present in the oral cavity 
suggests that one possible point of entry is the oral cavity.  
 
Another possible point of entry for bacterial remnants is the gut. Circulating LPS was 
previously shown to increase after the ingestion of high-fat meals by healthy adults. 
Study II found a pronounced increase in serum markers of inflammation after multiple 
high-fat meals; however, our data suggest this inflammation was not attributable to 
increases in circulating LPS. Indeed, circulating LPS levels appeared to have no effect 
on immune cell activation or systemic inflammation. This led us to investigate factors 
related to intestinal homeostasis, particularly focusing on factors such as alkaline 
phosphatases, which might affect the potency of intestinally derived LPS. In Study III, 
we found a general disturbance in factors related to gut homeostasis in patients with 
T1D. Specifically, low levels of fecal alkaline phosphatase found in patients with T1D 
contributed to increased LPS potency in the intestine, which in turn boosted intestinal 
inflammation.  
These studies help shed light on the potential routes of entry for bacterial remnants 



















Finland has the highest incidence of type 1 diabetes (T1D) worldwide, with 
approximately 30,000 currently diagnosed individuals within a population of just over 
5 million1. 
It is estimated that one-third of T1D patients develop renal disease within 20 years 
after disease onset2. Microvascular and macrovascular complications such as 
neuropathy, nephropathy, retinopathy, atherosclerosis and stroke are frequently 
observed in T1D patients with long disease duration and metabolic disturbance. 
Diabetic complications such as cardiovascular disease, atherosclerosis and 
nephropathy have been associated with elevated levels of inflammatory markers3-5. 
Continuous exposure to microbial agents partially explains the chronic inflammation 
reported in patients with T1D. Two microbial agents known to induce inflammation 
are bacterial DNA and endotoxin.  
The bacterial endotoxin lipopolysaccharide (LPS) is a unique glycolipid that serves as 
a component of the outer membrane in Gram-negative bacteria. In two recent 
studies, we reported that LPS activity is positively associated with inflammatory 
markers and the advancement of diabetic nephropathy6,7. Therefore, elevated levels 
of LPS may play a key role in the promotion and progression of diabetic complications. 
A better understanding of the origin and consequences of circulating LPS will help 
inform the development of treatments or interventions for chronic inflammation. 
However, currently, there is no method to determine the origin or type of bacterial 
LPS. Given that it is identifiable and classifiable, circulating bacterial DNA may help 
elucidate the origins and types of bacterial components found in circulation.  
High-fat diets trigger metabolic endotoxemia, defined as an increase in plasma LPS, in 
human and animal models8. This surge of bacterial LPS in the peripheral blood likely 
elicits the observed postprandial increases in leukocyte count and activation. Several 
recent studies in patients with cardiovascular disease, as well as healthy participants, 
have reported increased inflammation markers derived from both the innate and 
adaptive immune systems in response to a high-fat diet9-12.  
Intestinal inflammation and altered intestinal microbial profiles are thought to play 
key roles in lipid metabolism and the development of chronic, systemic low-grade 
 
inflammation13. Moreover, there is evidence of an imbalance in intestinal microbial 
profiles and disturbance of the primary intestinal defense system in patients with 
T1D14,i,15.  
Thus, there is undoubtedly a need for data regarding the sources and effects of 
circulating microbial remnants in patients with T1D. 
 
  
                                                        
i However, this does not rule out the possibility that locally elevated LPS (e.g. in the peripheral 




2 Review of the literature 
2.1 Diabetes 
Diabetes mellitus, henceforth referred to as diabetes, is a chronic, progressive 
metabolic condition characterized by elevated blood glucose. Globally, an estimated 
422 million people currently suffer from diabetes16. The World Health Organization 
(WHO) defines diabetes as a fasting plasma glucose concentration at or above 7.0 mM 
or a plasma glucose concentration of 11.1 mM two hours after the ingestion of a 75-g 
oral glucose load17. In a healthy individual, glucose concentrations are maintained by 
a balance between insulin secretion and insulin action. In contrast, patients with 
diabetes show impaired insulin secretion, decreased insulin sensitivity, or both.  
One common indicator of glucose control is glycated hemoglobin (HbA1c). HbA1c is 
formed when glucose binds to the hemoglobin proteinii, which is found within all red 
blood cells. HbA1c is measured from the blood and reflects long-term trends in 
glucose levels. HbA1c is often reported as a percentage, with <6% being a normal 
value and values above >6.4% being common in diabetes.  
In a healthy individual, insulin is secreted in both a constitutive and regulated 
manner18,19. In addition to low levels of constitutive insulin secretion, healthy 
pancreatic β cells release large bursts of insulin in response to elevated glucose levels. 
The concentration of glucose determines the magnitude of this insulin burst.  
Β cell glucose sensitivity is controlled by a multi-step regulatory pathway. Briefly, the 
protein glucose transporter 2 (GLUT2) internalizes glucose, which is processed and 
catabolized, generating ATP from ADP. The ATP-ADP ratio in β cells indirectly 
stimulates the fusion of insulin-containing vesicles with the plasma membrane, 
resulting in the release of insulin from the cell18. Higher glucose concentrations 
prompt larger numbers of β cells to release insulin, thereby increasing the 
concentration of circulating insulin. Elevated concentrations of circulating insulin, in 
turn, increase glucose uptake in peripheral tissues and lead to lower circulating 
glucose concentrations. 
                                                        
ii The glucose-bound protein is then said to be glycated or glycosylated. This is also mentioned in 
section 2.4.1 when discussing AGEs. 
 
2.2 Classification of Diabetes 
Diabetes is conventionally divided into two subgroups: insulin-dependent type 1 and 
non-insulin-dependent type 2 diabetes. Type 1 diabetes (T1D) is characterized by 
autoimmune destruction of the insulin-producing islet β cells and generally manifests 
itself early in life. The symptoms of T1D include fatigue, muscle loss, increased thirst 
and urination, blurred vision, erectile dysfunction, and pain or numbness in the hands 
and feet (http://www.nhs.uk). T1D may be accompanied by diabetic ketoacidosis, a 
life-threatening condition characterized by high levels of blood acids called ketones, 
which is triggered by insulin insufficiency. 
The more common type 2 diabetes (T2D) is a late-onset disease characterized by 
hyperglycemia caused by impaired insulin secretion, insulin resistance and increased 
glucose output by the liver20. T2D is generally diagnosed later in life and is often 
associated with obesity and metabolic syndrome (MetS). However, in recent years an 
increase in T2D in children and adolescents has been reported21. The symptoms of 
T2D include fatigue, hunger, increased thirst and urination, blurred vision, or pain or 
numbness in the hands and feet22.  
Three less common forms of diabetes are gestational diabetes, latent autoimmune 
diabetes in adults (LADA) and maturity-onset diabetes of the young (MODY). 
Gestational diabetes is defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy23. Similar to T1D, gestational diabetes is diagnosed using 
a glucose tolerance test; however, the cutoffs vary greatly24. Gestational diabetes 
often resolves itself in the early postnatal period. LADA presents the same clinical 
symptoms as T2D but also is characterized by islet autoimmunity25. LADA is generally 
diagnosed in young adults, but many LADA cases may be misclassified (e.g., as T1D or 
T2D) due to the application of inconsistent diagnostic criteria. MODY is an autosomal 
dominant condition with significant genetic heterogeneity26. Although there are six 
MODY subtypes, the three most common genes that are mutated in MODY patients 
are GCK, HNF1A and HNF4A27. An early-onset disease, MODY generally does not result 







Figure 1  The relative prevalence of types of diabetes. 
2.3 Type 1 Diabetes 
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-
producing islet β cells early in life.  
2.3.1 Epidemiology 
Globally, the incidence of T1D appears to be increasing at an alarming rate while the 
age of onset is decreasing29,30. Finland has the highest incidence of type 1 diabetes 
worldwide with an incidence of over 60 per 100,000 people1. In recent years, the 
incidence of T1D in Finland has increased significantly faster than anticipated; 
however, the latest data suggest this increase in incidence is leveling off1.  
 
Figure 2 Number of new cases of type 1 diabetes in children 0-14 years old per 100,000 
people 2015 31. 
 
 
Contradicting the theory of increasing incidence, studies from Sweden and Belgium 
have reported that the cumulative incidence of T1D has, in fact, remained steady since 
the late 1980s32,33. Hence, ostensible increases in incidence may be attributable to the 
diagnosis of earlier onset cases34. The concurrent decrease in incidence in older age 
groups may offset the increase in early childhood cases, a situation referred to as 
‘spring harvest’. Much of the epidemiological data on T1D has been collected in 
children under the age of 14, so the picture is far from clear at this point. However, in 
those studies that have included older cohorts, the shift to earlier diagnosis does not 
fully explain the reported increases in incidence. Studies from Finland, Italy and the 
UK have also demonstrated increased incidence in older age groups (under 40)30,35. 
Therefore, the epidemiological evidence points to an environmental component in the 
development of T1D. This has led researchers to investigate a myriad of influencing 
factors, from diet and lifestyle to infections. A better understanding of the factors that 
trigger T1D is integral to the development of future treatments. 
2.3.2 Pathogenesis 
T1D is characterized by polygenic inheritance with generally low penetrance36. 
Mutations in the HLA region of chromosome 6p21 are perhaps the most well-
characterized group of genetic risk markers, and approximately 30% of European T1D 
patients are heterozygous37. However, recent studies have reported a decrease in 
high-risk HLA genotype frequency among more recently diagnosed T1D patients. 
Combined with the rising incidence of T1D, these data suggest changing genetic and 
environmental factors are contributing to an increase in incidence among children 
who lack the high-risk genotypes38. 
Moreover, the disease prevalence within populations carrying genetic risk markers 
further implicates an outside force in triggering the disease36. To date, there have 
been a myriad of proposals regarding the precipitating event(s) in T1D39-41. A viral, 
bacterial, chemical or dietary factor, alone or in cooperation with other factors, may 
contribute to the initiation of autoimmunity in T1D patients.  
A detailed enumeration and explanation of the early events during the pathogenesis 
of T1D is outside the scope of this thesis. However, a brief glimpse of the early 




responses. These aberrant responses may also be related to the later development of 
diabetic kidney disease.  
Figure 3 (below) shows the theoretical steps in the development of autoimmune 
diabetes. Briefly, the initiating event triggers inflammationiii (B1), causing an effector 
T celliv response to be favored over that of regulatory T cells (Tregs) (C1). Concurrently, 
within the pancreatic β cells, interferon α (IFN-α) (B3) is upregulated followed by MHC 
class I proteins (C3). Autoreactive CD8 T cells recognize the proteins being presented 
by the MHC proteins and thus kill the β cells (C3). This releases β cell antigens that are 
then picked up by antigen presenting cells (APCs) (C3) and brought to the lymph node 
(C2), where they stimulate CD8 T cell proliferation (D2) and the production of insulin 
autoantibodies (D1). The autoreactive T cells then migrate to the pancreas (D3), where 
they secrete perforin, TNF-α and IFN-γ to continue and enhance the autoimmune 
assault. Β cell destruction releases new proteins into circulation, priming subsets of 
CD4 and CD8 T cells that are specific to new epitopes. This is termed epitope 
spreading, and it results in T cells specific for new β cell proteins (E2). The secondary 
assault on β cells is then specific for a broader range of proteins and is, therefore, 
more severe than the first. The increased inflammation also appears to trigger the 
proliferation of β cells, while Tregs may occasionally slow the autoimmune destruction 
of β cells, resulting in a constant fluctuation in the patient’s overall β cell mass or 
function (F3/yellow line). Clinical diabetes is generally diagnosed when the β cells are 
unable to produce sufficient insulin to prevent hyperglycemia. The ‘honeymoon 
phase’ (below F3) is a generally short period soon after diagnosis when the β cells are 






                                                        
iii For a description of this information, please see section 2.7.  
iv For a brief explanation of the functions of different T cell types, please see section 2.6. 
 
 
Figure 3 The proposed steps in the etiology of type 1 diabetes. Adapted from42. 
2.3.3 Healthcare Expenditures 
As the incidence increases and the age of onset decreases, the costs related to 
diabetes care will increase. International data on health care expenditures specifically 
associated with T1D is scarce. Health care costs due to all diagnosed forms of diabetes 
account for approximately 12% of total global healthcare expenditures43. According 
to the International Diabetes Federation, individual nations generally allocate 
between 5% and 18% of total healthcare costs to the treatment of diabetes. This 
includes estimated costs borne by individuals and by the government. There is also 
evidence that the annual cost of T1D is significantly higher than that of T2D on a per 
patient basis44. Importantly, the development of diabetic complications doubles the 
cost of treatment45. 
As one of the leading causes of death worldwide, the human cost of diabetes is 
substantial. There are an estimated 1.5 million deaths related to elevated glucose 
levels, and this number is expected to double by 203017. It may be possible to stem 




treatment for all types of diabetes, particularly aiming to prevent the development of 
diabetic complications.  
 
Figure 4 Annual healthcare expenditure per patient with diabetes for 2015, in USD31. 
2.4 Diabetic complications 
Broadly speaking, diabetic complications can be separated into two categories: 
macrovascularv and microvascularvi,46. Together, these vascular diseases represent 
the primary cause of morbidity and mortality in patients with T1D. Microvascular and 
macrovascular complications are frequently observed in T1D patients with long 
disease durations and metabolic disease47.  
While the precise pathogenesis of diabetic complications is not yet fully understood, 
morbidity and mortality due to cardiovascular disease, atherosclerosis and 
nephropathy have been associated with elevated levels of inflammatory markers3-5. 
Moreover, there is growing evidence that the pathogenesis of diabetic complications 
is also associated with bacterial infections (further discussion below)7.  
Hyperglycemia may play an integral role in immune system weakening and the 
progression of vascular complications in diabetic patients46. This hypothesis is 
supported by studies showing that hyperglycemia is associated with increased 
complications and mortality in both patients with T1D and patients with critical 
illnesses other than diabetes48,49.  
                                                        
v e.g. Coronary artery disease, peripheral arterial disease, stroke. 
vi e.g. Diabetic nephropathy, neuropathy, retinopathy. 
 
2.4.1 Microvascular Complications 
Microvascular complications of diabetes include diseases such as nephropathy, 
retinopathy and neuropathy. This thesis focuses on diabetic nephropathy and to a 
lesser extent diabetic retinopathy.  
2.4.1.1 Diabetic Nephropathy 
Diabetic nephropathy is a degenerative condition characterized by the progressive 
loss of renal (kidney) function50. An estimated one-third of T1D patients develop renal 
disease 15-20 years after disease onset2.  
The function of the kidney is to regulate the balance of electrolytes, maintain pH 
homeostasis and filter organic metabolic waste products such as phosphates, sulfates 
and nitrogen compounds. The basic functional subunit of the kidney is the nephron, 
which filters the blood and reabsorbs the water, electrolytes and other factors needed 
to maintain homeostasis. The waste products collected by the nephron are eventually 
excreted in the urine.  
While the healthy kidney filters out metabolic wastevii, damaged kidneys aberrantly 
permit beneficial proteins such as serum albumin to leak into circulation. Damaged 
kidneys are also less efficient at filtering metabolic waste, leading to elevated levels 
of waste in circulation. If left unchecked, these elevated concentrations of metabolic 
waste lead to toxicity. 
The glomerulus is a nephron subunit that represents the first stage of the filtration 
process in the kidneys. The glomerulus is partially encapsulated by the podocyte, 
which works with the glomerulus to form a filtration barrier. In diabetic kidney 
disease, glomerular basement membranes are thickened, gradually lose their 
permeability and are subject to leukocyte adhesion51,52. Moreover, in diabetic kidney 
disease, podocytes are less numerous and show signs of structural injury and 
decreased functionality, leading to the leakage of serum proteins such as albumin into 
the urine53,54. Urine albumin levels are therefore useful for assessing levels of kidney 
damage.  
                                                        




A damaged kidney in the context of diabetes is termed diabetic nephropathy. 
Definitions of diabetic nephropathy are presented in Table 1. Diabetic nephropathy is 
among the most serious diabetic complications and may lead to decreased quality of 
life and increased risk of early mortality. Furthermore, diabetic nephropathy is the 
strongest risk factor for cardiovascular outcomes and is associated with metabolic 
syndrome55.  
In later stages of diabetic nephropathy, dialysis and kidney transplant may be 
required. 
 
Nephropathy status Definition 
Normal AER UAER<30 mg/24 h or UAER<20 μg/min* 
Microalbuminuria 30<UAER≥300 mg/24 h or 20<UAER≥200 μg/min* 
Macroalbuminuria UAER≥300 mg/24 h or UAER≥200 μg/min* 
End Stage Renal Disease Dialysis or transplant required 
Table 1 albumin excretion rate 
determined by a timed urine collection. *Denotes cutoffs for overnight collection. 
Chronic hyperglycemia is a major risk factor that is integral to the development of 
diabetic nephropathy. One underlying mechanism is the formation and accumulation 
of advanced glycosylated end products (AGES)56. AGES are proteins or lipids that have 
become bound to a sugar molecule and are increased in patients with T1D with a 
further increase in patients with diabetic nephropathy52,57. AGEs may then be 
deposited on the vascular wall or in the glomerulus, thereby causing thickening of the 
basement membrane.  
 
  Definitions of nephropathy status. UAER refers to the urinary 
 
AGEs also modulate inflammation and immune cell function via the receptors RAGE 
and AGE-R258-60. AGEs may, therefore, contribute to podocyte damage through their 
proinflammatory effectsviii.  
While there is only limited knowledge regarding the pathophysiological mechanisms 
underlying podocyte damage and loss in diabetic nephropathy, recent evidence 
suggests inflammation plays a role61. Indeed, in two recent studies, we reported an 
association between diabetic nephropathy and elevated levels of inflammatory 
markers and bacterial endotoxins6,7. 
2.4.1.2 Diabetic Retinopathy 
With approximately 360,000 new cases per year in the US alone, diabetic retinopathy 
(proliferative retinopathy/diabetic macular edema) may be the most prevalent 
diabetic microvascular complication and frequently precedes diabetic nephropathy46. 
Indeed, one large study found the 25-year cumulative incidence of macular edema to 
be 29% in patients with T1D62. The incidences of diabetic proliferative retinopathy and 
diabetic macular edema are roughly equivalent63. However, proliferative retinopathy 
is the most severe form of retinopathy and is the most common reason for laser 
treatment in patients with T1D64. Similar to diabetic nephropathy, hyperglycemia is 
associated with the development of diabetic retinopathy. It is therefore unsurprising 
that the incidence of retinopathy is positively associated with the development of 
nephropathy. Diagnosis of retinopathy is based on direct inspection of the retina via 
fundus photography or direct ophthalmoscopy65. While monitoring and clinical 
management of risk factors are the preferred treatment option for retinopathy, 
proliferative retinopathy may be treated using methods such as photocoagulation and 
vitrectomy66.  
 
                                                        
viii AGEs induce NF-κB-based inflammation both through their receptors as well as directly through 
TLR458-60. For more information on the relevance of this inflammation in diabetic nephropathy, 




2.4.2 Macrovascular Complications  
Macrovascular complications include diseases such as angina, myocardial infarction, 
angioplasty, coronary artery bypass graft, stroke, claudication, or peripheral bypass67. 
While macrovascular complications are not discussed herein, hyperglycemia-
mediated inflammation is also implicated in their development68. 
2.5 Metabolic syndrome 
The first formal definition and list of diagnostic criteria for metabolic syndrome (MetS) 
were given in 1998 by the World Health Organization69. This statement implicated 
several metabolic and underlying risk factors in the development of the condition and 
identified certain combinations of risk factors as characteristic of the disease, which 
were intended for use as diagnostic criteria. These diagnostic criteria have since been 
challenged and modified, leading to some confusion regarding how to diagnose 
patients with the syndrome70,71. Despite disagreement over the diagnostic criteria, it 
is generally acceptable to apply the term MetS to the condition characterized by the 
presence of multiple metabolic risk factors for cardiovascular disease and diabetes72. 
Atherogenic dyslipidemia, elevated blood pressure, elevated glucose, a 
proinflammatory state, and a prothrombotic state are the five primary metabolic risk 
factors considered when diagnosing MetS 71. In addition to metabolic risk factors, 
there are many underlying risk factors that contribute to MetS, including obesity, 
physical inactivity, blood pressure, atherogenic diet, primary insulin resistance, 
advancing age and hormonal factors. The International Diabetes Federation Task 
Force on Epidemiology and Prevention, the National Heart, Lung, and Blood Institute, 
the American Heart Association, the World Heart Federation, the International 
Atherosclerosis Society, and the International Association for the Study of Obesity 
released a joint statement on the definition of MetS in 2009, requiring that patients 
meet three of the five criteria presented in Table 2. 
As shown in recent analyses of large prospective studies, MetS is an independent risk 
factor for the development of cardiovascular events and cardiovascular and diabetes-
related mortality, even after adjustment for traditional risk factors55. 
 
 
Joint Statement Criteria for Metabolic Syndrome 
Elevated BP (≥130/85 mm Hg or on drug therapy) 
Plasma TG ≥150 mg/dL, 1.7 mmol/L 
HDL < 40 mg/dL (1.0 mmol/L) (M), < 50 mg/dL (1.3 mmol/L) (F) 
Fasting glucose ≥ 100 mg/L 
Elevated waist circumference (varies by country) 
 
Table 2 e. BP is blood pressure. TG is circulating triglycerides. 
HDL is circulating high-density lipoproteins. (M) and (F) refer to criteria for men and women, 
respectively. Based on the Joint Statement73. 
2.6 The Innate and Adaptive Immune System 
In humans, there are two classes of the immune response to invading pathogens: 
innate (natural, or a priori) and adaptive (or acquired) immunity. The adaptive 
immune response is primarily mediated by B and T cell lymphocytes and characterized 
by lymphocyte recognition of an immunogenic epitope followed by cellular signaling 
and proliferation. Depending on the baseline prevalence of lymphocytes that are 
reactive towards an epitope, as well as antibody affinity, a full response may take 
weeks to mount. 
In contrast, the innate immune response is an evolutionarily conserved, ancient 
mechanism that facilitates a rapid response to components of invading pathogens, 
which are generally referred to as pathogen-associated molecular patterns (PAMPs) 
(see Table 3 in section 2.8) ix . Unlike the adaptive immune response, the innate 
immune response is based on soluble and cellular pattern recognition receptors 
(PRRs)x expressed throughout the organism. Upon ligation of a PAMP, innate immune 
receptors rapidly mount a first-line response against the invading pathogen. 
2.7 Inflammation in Diabetes 
According to Buchman et al., “inflammation is a cooperative response involving 
multiple cell types, orchestrated both locally and remotely, and affecting the host at 
multiple levels of resolution (from organism to gene expression)” 74.  
                                                        
ix For example, lipopolysaccharide. 
x For example, Toll-like receptors. 
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When antigen presenting cells come into contact with a pathogen or a component 
thereof, they release a number of cytokines and chemokines. The cytokines and 
chemokines (further discussion in section 2.11) that are released are called 
inflammatory markers or mediators and are responsible for the vasodilatation and 
cellular permeability that manifest as redness, swelling and heat.  
Aberrant regulation of the inflammatory process is thought to be the underlying cause 
of many diseases, including autoimmune disorders, some cancers, allergies, asthma, 
sepsis, atherosclerosis, and neurodegenerative diseases75. Systemic and local 
inflammation are widely believed to play roles in the pathogenesis and progression of 
T1D through the aberrant secretion of or reaction to inflammatory markers76.  
There is evidence that pro-inflammatory cytokine secretion is dysregulated in T1D. 
Two recent studies have demonstrated increased cytokine secretion in response to 
bacterial lipopolysaccharide (LPS) stimulation in patients with T1D compared to 
healthy participants77,78. 
Even without experimental stimulation, T1D patients exhibit increased levels of 
inflammatory cytokines compared to healthy controls79,80. In particular, IFN- α, 
interleukin-1β (IL-1β), IFN- γ and CXCL-10 levels are elevated in recent-onset patients. 
In patients with a long history of T1D, increased levels of inflammatory markers 
positively correlate with the progression of diabetic complications such as 
cardiovascular disease, atherosclerosis and nephropathy, as well as all-cause 
mortality3-5.  
Given that researchers have reported increased stimulation capacity in human 
immune cells and increased concentrations of circulating ligands that are able to elicit 
inflammatory responses, there appear to be myriad causes of elevated inflammation 
in T1D patients. However, a better understanding of the causes and consequences of 
increased inflammation may help researchers develop treatments to forestall the 
development of diabetic complications. 
2.8 Bacterial Lipopolysaccharides and Toll-like Receptor 4 
Lipid-soluble lipopolysaccharide (LPS, also known as endotoxin) is a PAMP that is often 
used to model the effects of bacterial infection. LPS is a component of the outer 
membrane of Gram-negative bacteria81. Figure 5 illustrates the composition of the LPS 
 
molecule and its interactions with other components of the bacterial cell envelope. 
LPS is composed of a conserved, hydrophobic lipid A domain attached to sugar chains 
of variable length82. The sugar chain is subdivided into three domains. Two core 
oligosaccharide domains are directly attached to the lipid A domain, followed by the 
distal O antigen domain (Figure 5).  
Lipid A is produced constitutively and is highly conserved between bacterial strains83. 
As an integral component of the outer membrane of Gram-negative bacteria, Lipid A 
is essential for the growth and maintenance of bacterial colonies. The extremely high 
level of homologyxi of the bacterial LPS core makes it a prime target for the innate 
immune system.  
LPS is commonly measured using the limulus amebocyte lysate (LAL) assay84. This 
assay measures LPS activity and approximately translates into biologically active, free 
LPS levels. The LAL assay utilizes a slightly modified amebocyte extract called Limulus 
polyphemus from the North American horseshoe crab. The introduction of LPS to this 
mixture initiates a biochemical cascade ending in cleavage of the chromophore p-
nitroaniline and the development of a yellow color.  
 
 
Figure 5 The structure of LPS. Based on83. 
 
 
The inflammatory and immunostimulatory effects of LPS have been well-
characterized in humans85-88. Injected LPS has been applied in humans as a model for 
the biological response to infection85. In animal models, LPS has also been used to 
                                                        
xi While the core of LPS is rather homogenous, LPS molecules are highly heterogeneous, 




induce kidney failure89. Similarly, endogenous serum LPS activity levels are associated 
with markers of inflammation, as well as the advancement of diabetic nephropathy in 
T1D6,7.  
LPS triggers inflammation and immune responses via the interaction between the lipid 
A region of LPS and toll-like receptor (TLR)-4, which is located on the surface of 
immune and epithelial cells. TLRs are a well-characterized class of transmembrane 
proteins that detect components of infectious agents and activate host innate and 
adaptive immune systems in response to pathogen binding (Table 3). 
PRR PAMP 
TLR1 Triacyl lipopeptide, with TLR2 
TLR2 Bacterial peptidoglycan (PGN) 
TLR3 Double-stranded RNA (dsRNA) 
TLR4 Lipopolysaccharide (LPS) 
TLR5 Flagellin 
TLR6 Lipoteichoic acid, diacyl lipoproteins, zymosan 
TLR7 Single-stranded RNA 
TLR8 Single-stranded RNA 
TLR9 Unmethylated CpG DNA 
TLR10 Diacyl lipopeptide, with TLR2 
Table 3 Pattern recognition receptors (PRRs) and their associated pathogen-associated 




Figure 6 Intracellular signaling pathway for common PRRs. Based on 91. 
 
As shown in Figure 6, the primary intracellular signaling pathway for TLR4 utilizes the 
MyD88 adaptor protein to trigger the NF-κB inflammatory pathway (discussed further 
in section 2.10)92. TLR4 also triggers immune responses via NF-κB-independent 
pathways, including the interferon regulatory factor (IRF) pathway. However, the IRF 
pathway will not be discussed in detail herein.  
Recently, it has become increasingly clear that LPS and TLR4 play central roles in the 
progression of diabetic kidney disease. In humans, a large prospective study showed 
that LPS activity levels (measured using the LAL assay) predict deteriorating renal 
function7. Patients whose renal function deteriorated had significantly higher LPS 
activity levels at baseline when compared to those patients whose renal function did 
not deteriorate. Although the origin of the LPS was not known, patients with T1D 
suffer from an increased rate of infections93. Significantly, the relative prevalence of 
gastrointestinal infections in patients with T1D was more than double the prevalence 
observed in healthy controls. However, there is no validated method for determining 




Kidney biopsies from patients with T1D and diabetic nephropathy demonstrate 
increased TLR4 expression94. Moreover, there appears to be a molecular link between 
TLR4 activation and injury in human kidneys. Indeed, according to recent in vitro 
reports, LPS activation of TLR4, as well as diabetic serum, causes podocyte apoptosis61. 
This is particularly intriguing given that LPS-induced apoptosis is blocked and partially 
reversed by TLR4 blockade. Furthermore, TLR4 knockout reduces renal inflammation 
and protects against kidney damage95. Strengthening the case that LPS is a major 
apoptosis-triggering factor in diabetic serum, sera from non-diabetic patients with 
high LPS activity levels were found to induce apoptosis in kidney cells96. This pro-
apoptotic activity was abrogated upon incubation with polymyxin B, a compound that 
sequesters LPS from circulation and therefore inhibits TLR4 binding. 
In addition to increased LPS activity levels, there have been numerous reports of 
increased TLR4 expression in T1D monocytes78,97,98. Moreover, this reported increase 
in TLR4 coincides with increased LPS activity in circulation97. Increased LPS levels in 
combination with increased TLR expression may partially explain the elevated levels 
of inflammatory markers in circulation in patients with T1D98,76. 
Thus, LPS binding to TLR4 exerts a direct apoptotic effect on kidney cells in vitro and 
is likely a driving force underlying the development of diabetic kidney disease.  
2.9 Bacterial DNA and Toll-Like Receptor 9 
Another common substance that is used to model bacterial infection in vitro is 
bacterial DNA, which is recognized by TLR9 (Table 3). Bacterial DNA contains a high 
frequency of unmethylated CpG motifs, which TLR9 recognizes99. In contrast, 
mammalian DNA contains a much lower frequency of CpG motifs, and these are 
generally methylated. Upon the ligation of unmethylated CpG DNA, TLR9 activates the 
NF-κB and IRF pathways, similar to LPS ligation of TLR4.  
Although the precise half-life of bacterial DNA in circulation is not known, studies have 
shown that other forms of DNA injected into humans and animals are rapidly cleared 
from circulation100,101. However, it is unlikely that bacterial DNA enters circulation as 
free DNA; rather, it enters through intact or damaged bacteria. Indeed, bacterial DNA 
has been identified in certain body compartments up to 7 years after infection102.  
 
Bacterial DNA in circulation correlates with inflammation, oxidative stress and the 
presence of bacterial translocation into circulation in the absence of overt infection103-
105. However, the origin of circulating LPS and bacterial DNA is not known, although 
there is evidence implicating the oral cavity and the gut as potential sources of 
bacterial components in circulation. The human intestine is home to a large bacterial 
population. One early study investigating the diversity of the human microbiome 
sequenced bacterial ribosomal DNA and created a phylogenetic tree using a 99% 
similarity cutoff106. This phylogenetic tree identified 395 phylotypes, 62% of which 
were novel and 80% of which represented sequences that had not previously been 
cultivated at that time. While there is a high degree of diversity in the intestinal flora, 
the most prevalent bacterial phyla identified were Firmicutes and Bacteroides. 
Proteobacteria, Actinobacteria, Fusobacter, and Verrucomicrobia were also present 
but to a noticeably lesser degree. Along with the gut, the oral cavity represents one of 
the most likely sources of bacterial remnants found in circulation. Periodontitis, an 
inflammatory gum disease, is more prevalent in patients with T1D than the general 
population107. Studies in patients with periodontitis have shown that mastication 
increases the levels of circulating endotoxins, suggesting bacterial components enter 
the bloodstream through infected gums108.  
2.10 NF-κB 
Cells employ a cascade of protein interactions to effectively translate PRR ligation into 
cellular responses. The NF-κB pathway is a major signal transduction pathway initiated 
upon TLR4 binding to its ligand LPS. NF-κB refers to a homologous, highly conserved 
group of DNA-binding proteins within the Rel/dorsal family109. These cytoplasmic 
proteins are almost universally expressed and involved in cell stress responses. 
Although NF-κB is involved in cell survival, proliferation and neural plasticity, the focus 
herein is its effects on inflammation.  
NF-κB is integral to the development of diabetes. NF-κB knockout mice are resistant 
to streptozotocin-induced diabetes110. Furthermore, NF-κB inhibition protects 
pancreatic islet cells from cytokine-induced apoptosis111. Additionally, NF-κB is 




Therefore, NF-κB may be a promising therapeutic target for protection against 
diabetogenesis and the progression of diabetic complications. 
2.11 Cytokines 
When investigating the roles of cytokines and chemokines in the pathophysiological 
processes underlying diseases, it is important to note that these inflammatory 
mediators often trigger a wide array of cellular responses. In addition to the regulation 
of immune responses, cytokines stimulate proliferation, differentiation and apoptosis. 
They also influence cell-cell interactions, modulate the adaptive immune process and 
induce or suppress the production of or responsiveness to other cytokines. 
The effects of cytokines on renal injury were first described in 1991 when Hasegawa112 
reported the ability of diabetic kidney glomerular basement membranes and 
mesangial matrix from mice to induce TNF-α and IL-1β secretion in cultured 
macrophages. Shortly thereafter, Sekizuka et al. reported elevated IL-6 concentrations 
in patients with diabetic nephropathy113.  
These early studies opened the door to a number of studies investigating the effects 
of cytokines on diabetic nephropathy. It is now well established that elevated cytokine 
concentrations are associated with the progression of diabetic complications3-5. 
Specifically, markers of inflammation such as IL-18, IL-6, IL-1β, CRP, MBL, TNF-α and 
ICAM-1 are elevated in patients with diabetic nephropathy5,114-117. Studies examining 
the progression of diabetic complications and upstream mediators of inflammation 
such as LPS-TLR4-NF-κB (see above) suggest these cytokines may be directly linked to 
the initiation of kidney cell apoptosis and the associated decline in renal function.  
Upon exposure to a broad array of cytokines, pancreatic β cells modify their 
expression of numerous genes, eventually leading to apoptosis. Cardozo et al. 
reported more than 66 genes in rat pancreatic β cells that are differentially expressed 
upon exposure to cytokines118,119. Events during the early pathogenesis of diabetes 
may also play a role in the eventual progression of diabetic complications. 
2.11.1 Tumor Necrosis Factor Alpha 
Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine that has long been 
known to play a role in insulin resistance120. It is produced in a wide array of cells, 
 
including renal cell types and kidney-resident immune cells121-124. Furthermore, TNF-
α is commonly upregulated in response to TLR4 binding to LPS125. TNF-α directly 
induces renal cell damage and apoptosis126,127. Moreover, it initiates a local pro-
apoptotic milieu by triggering the production of inflammatory mediators and other 
proteins involved in immune cell recruitment128,129. 
During earlier stages of diabetic kidney disease, TNF-α induces the early signs of renal 
dysfunction, renal hypertrophy and hyperfiltration in rats130,131, which are measured 
in humans as the albumin excretion rate. 
2.11.2 IL-1β 
Similar to TNF-α, interleukin (IL)-1β is produced at sites of local inflammation and is a 
pleiotropic inflammatory mediator. At the genetic level, polymorphisms in the gene 
encoding IL-1β have been associated with the risk of diabetic kidney disease132, 
potentially due to the known effects of IL-1β on renal hemodynamics or vascular 
endothelial cell permeability133,134. Recently, Shahzad et al. demonstrated that 
increased concentrations of IL-1β in circulation proceeded albuminuria and 
glomerular extracellular matrix accumulation in a murine model of T1D135. 
Furthermore, inhibition of IL-1 receptor signaling reduced albuminuria. Taken 
together, these data suggest IL-1β up-regulation plays a key role in the development 
of diabetic nephropathy.  
2.11.3 IL-6 
In an early study, we showed that one of the primary regulators of inflammation in 
the human body, IL-6, is associated with progressive diabetic nephropathy115. 
Furthermore, polymorphisms in the IL6 gene promoter are associated with diabetic 
kidney disease136. Similar to TNF-α and IL-1β, the mechanisms underlying the 
association between IL-6 and diabetic kidney disease involve a wide array of pathways. 
In particular, IL-6 is involved in endothelial permeability, the induction of mesangial 




2.12 Fat-enriched diets 
High-fat diets have been shown in human and animal models to trigger metabolic 
endotoxemia, defined as an increase in plasma LPS11,138. Although the mechanism 
underlying the internalization of LPS has yet to be confirmed, LPS is most likely 
internalized by the Golgi complex in intestinal epithelial cells, where it is then 
transported into circulation by chylomicrons that are synthesized in response to the 
fat load10,139,140. Increased chylomicron production triggered in response to a high-fat 
diet is proposed to increase the transport of LPS from the gut into circulation.  
This surge in bacterial LPS in the peripheral blood likely also elicits the observed 
postprandial increase in leukocyte count and activation141-143. Several recent studies 
in patients with cardiovascular disease, as well as healthy participants, have reported 
increases in inflammation markers from both the innate and adaptive immune 
systems in response to a high-fat diet9-12. Additionally, a high-fat diet has been shown 
to increase LPS sensitivity and trigger the release of inflammatory markers, notably IL-
6 and TNF-α, in a murine model143,144.  
2.13 Intestinal Inflammation in T1D 
Intestinal inflammation and altered intestinal microbial profiles are thought to play 
key roles in lipid metabolism and the development of chronic, systemic low-grade 
inflammation13. Previous studies have revealed systemic inflammation without 
evidence of elevated leukocyte cytokine production in response to a series of high-fat 
meals (Study II). We observed no changes in cytokine secretion or LPS sensitivity in 
immune cells; therefore, commonly observed postprandial inflammation likely 
originates in peripheral tissues and is not triggered by systemic postprandial LPSxii. 
Furthermore, patients with T1D exhibit impaired triglyceride metabolism in response 
to a high-fat meal14. Taken together, these observations suggest an imbalance in 
intestinal microbial profiles and concomitant disturbance in the primary defense 
system in the intestines.  
                                                        
xii However, this does not exclude the possibility that locally elevated LPS (e.g. in the peripheral 
tissues) might be a contributing factor to postprandial inflammation.  
 
Evidence has suggested the presence of subclinical inflammation in the intestines of 
patients with T1D15. Indeed, T1D shares several genetic and immunological 
components with inflammatory bowel disease (IBD)145-147. Furthermore, these 
diseases share an increased risk of cardiovascular complications148-150. Previous 
studies have shown an increased prevalence of IBD in patients with T1D but not an 
increase in T1D in patients with IBD151,152. These studies also found similar HbA1c 
levels in T1D and T1D + IBD populations, suggesting the increased prevalence is not 
secondary to poor glycemic control.  
2.14 Alkaline phosphatases 
Alkaline phosphatases (APs) are a group of enzymes derived from the liver, bone, 
placenta and intestine that are found in circulation and feces153. The intestinal isoform 
of AP (IAP) plays a key role in the maintenance of intestinal homeostasis154,155. IAP, a 
protein produced in the enterocyte brush border, is able to hydrolyze monophosphate 
esters156. IAP detoxifies LPS through dephosphorylation of the lipid A moiety 154,155. 
Triglycerides are transported into circulation through chylomicrons, which are known 
to incorporate IAP and LPS. Therefore, both circulating IAP and LPS increase upon the 
ingestion of fatty meals157. However, we recently showed that this postprandial 
increase in LPS activity levels is rather modest and not seen in patients with T1D14. 
Furthermore, in an earlier study, we found no association between circulating LPS and 
markers of inflammation14. By contrast, injected LPS rapidly upregulates inflammatory 
cytokines. 
IAP is critical for the regulation of fatty acid absorption, and IAP deficiency leads to 
the development of metabolic syndrome in mice155,159. Furthermore, IAP insufficiency 
has been observed in intestinal diseases related to T1D, such as inflammatory bowel 
disease and celiac disease160-162. However, these studies did not control for blood type 
or secretor phenotype, which is a genetic component that strongly affects IAP 
activity157. IAP supplementation may nevertheless represent one potential 
therapeutic strategy for inflammatory bowel disease and metabolic syndrome163,164.  
Although IAP expression has a strong genetic component, it is also influenced by diet 
and participates in bidirectional regulation with the gut microbiota, i.e., IAP expression 




One mediator of the IAP-microbiota interaction is the short-chain fatty acid butyrate. 
Butyrate, along with the short-chain fatty acids acetate and propionate, is produced 
in the colon by commensal microbiota that ferment complex carbohydrates and plant 
polysaccharides165. While butyrate serves as an energy source for the colonic 
epithelium, it has also been reported to enhance both IAP expression and activity166. 
Given that butyrate is a microbial fermentation product of dietary components, it is 
not surprising that diet indirectly regulates the production, secretion and biological 




3 Aims of the Study 
Based on our prior observations, we hypothesized that bacterial infections play a 
significant role in the development of diabetic kidney disease. Although a number of 
previous studies have reported increased morbidity and mortality due to T1D-
associated infections, the cause of this increased susceptibility remains unclear. There 
is evidence of a dysregulated innate immune system in T1D; however, a concrete link 
between this dysregulation and differential inflammation and susceptibility to 
infections has not been established. The primary goal of the present study was to 
identify biological factors that modulate bacteria-mediated inflammation in patients 
with T1D. 
 
The specific aims of studies I-III were as follows: 
 
I. Determine the origin of bacterial DNA in circulation and investigate 
correlations with markers for immune response and inflammation. 
II. Determine the acute effects of high-fat meals on inflammation and the 
inflammatory response of antigen presenting cells in the context of T1D. 
III. Determine the role of intestinal alkaline phosphatase in intestinal 






4 Materials and Methods 
4.1 Study Subjects 
Adult subjects with and without T1D were investigated in studies I-III (Table 4). 
Healthy non-diabetic control subjects (NDC) and patients with T1D were 
selected from the Finnish Diabetic Nephropathy Study (FinnDiane). T1D was 
defined as the onset of diabetes before the age of 40 years and permanent 
insulin treatment initiated within 1 year of diagnosis. Normal albumin 
excretion was defined as AER<20 μg/min or <30 mg/24 h. Macroalbuminuria 
was defined as AER≥200 μg/min or ≥300 mg/24 h 
 
  T1D NDC Macro 
Study I-DNA 14 (8/6) 10 (5/5) - 
Study I-Serum Ab 200 (97/103) 200 (94/106) - 
Study II 11 (6/5) 11 (7/4) - 
Study III 36 (14/22) 41 (20/21) 10 (7/3) 
 
Table 4  Participants in each of the three studies. Numbers represent total numbers of 
subjects (male/female). NDC: Non-diabetic controls; macro: patients with T1D and 
macroalbuminuria.  
 
Subjects within the circulating DNA study (Study I) 
Participants were recruited by the FinnDiane Study. Study I included 10 non-
diabetic control subjects and 14 patients with T1D. Unless otherwise noted, all 
tests were performed using blood samples taken from these subjects. We 
hypothesized that individuals with high LPS harbored higher overall bacterial 
loads. Therefore, all selected subjects belonged to the highest LPS quartile 
within their group. For serum antibody analysis, additional healthy controls (n 
= 200) and patients with T1D (n = 200) were randomly selected from the 
FinnDiane Study. 
 
Subjects within the fat tolerance study (Studies II and III) 
 
Participants were recruited by the FinnDiane Study. Study II included 11 
patients with T1D and 11 controls. Study III included 41 non-diabetic controls, 
36 patients with type 1 diabetes and normal albumin excretion and 10 patients 
with type 1 diabetes and macroalbuminuria. The inclusion criteria for studies II 
and III were 1) age 18-65 years; 2) no use of antibiotics during the past month; 
and 3) no trips outside the Nordic countries during the past month.  
In studies II and III, on the investigation day, participants were given three 
energy-rich meals (2600 kcal): breakfast (at 8:00 - 965 kcal, 58% of total energy 
(E%) from fats), lunch (12:00 - 870 kcal, 44 E% fats), and dinner (16:00 - 779 
kcal, 46 E% fats). Blood samples were drawn after overnight fasting and every 
two hours until 18:00 hrs. Urine was collected during the research day. 
Participants collected two fecal samples before and after the research day, 
approximately one week apart. The samples were then sent to the study center 
for further processing. Measured analytes in these two samples strongly 
correlated. The samples were therefore used as biological replicates. 
Participants in Study III completed a three-day food record prior to the day of 
investigation. Dietary intake was analyzed as previously described 167. 
Information on the use of medication was recorded with a standardized 
questionnaire.  
4.2 Laboratory Methods 
4.2.1 Measurements from serum, plasma and cell culture supernatant 
Analysis of serum LPS activity – Studies I, II and III  
In Studies I and III, serum LPS activity was measured kinetically from serum samples 
using the Limulus amoebocyte lysate assay (LAL, Hycult, Uden, Netherlands). Briefly, 
color formation at 405 nm was recorded every 2 min for a total of 40 min. We 
subtracted the minimum absorbance value from the maximum value to correct for 
interference caused by postprandial triglycerides and hemolysis 168. 
 




Serum concentrations of IL-6, TNF-α, IL-1β, IFN-α, IL-10, IFN-γ, IL-12, MIP-1β, IL-1α, IP-
10, MIP-1α, IL-8, and MCP-1 were assayed using the FlowCytomix Multiple Analyte 
System (eBioscience, Vienna, Austria) according to the manufacturer’s instructions. 
Data were analyzed using FlowcytomixPro (eBioscience, Vienna, Austria) and Prism 
(GraphPad Software, Inc., La Jolla, CA, USA). Standard curves were generated, and 
concentrations were calculated using Prism. 
 
Intracellular cytokine staining and LPS stimulation – Study II 
The production of IL-1β, TNF-α-, and IL-6 was assayed in resting and PBMCs stimulated 
with exogenous LPS by performing intracellular staining followed by flow cytometry. 
Briefly, immediately after collection, 200 μl of sodium heparin blood was incubated 
with or without 100 ng/ml E. coli LPS (strain 0111:B4; DIFCO 3122-25-8 Detroit, MI, 
USA) for 4 h at 37°C. After 1 h, GolgiStop (BD Biosciences, San Jose, CA, USA) was 
added. Thereafter, blood was mixed with surface marker antibodies to identify 
monocytes and myeloid dendritic cells (mDCs) (CD14 PE-Cy5.5, CD19 PE-Cy5.5, and 
CD1c APC) and incubated for 20 min in the dark at room temperature (RT). Red blood 
cells were then lysed using FACS Lysing Solution (BD Biosciences). White blood cells 
were pelleted out of solution via centrifugation and washed twice with and fixed with 
4% paraformaldehyde in PBS. The cells were then permeabilized using BD Perm/Wash 
according to the manufacturer’s instructions and stained for intracellular cytokines 
using IL-1β FITC, TNF-α-PE, and IL-6 PE or isotype controls. Staining controls were 
prepared in the same way using 100 μl of blood. 
This stimulation was performed on whole blood; however, LPS activity levels 
with 100 ng/ml E. coli were tested under various in vitro conditions, including 
cell culture medium supplemented with 10% fetal calf serum. An activity level 
of 2.01 was observed in 10% serum-supplemented medium (unpublished 
data). In comparison, healthy adult serum LPS activity levels range between 0.1 
and 0.2.  
 
Serum measurements of CRP, AP, lipids, and clinical parameters – studies I, II, and III 
High-sensitivity C-reactive protein (hsCRP) was measured in the serum via 
immunoprecipitation (Thermo Scientific, Vantaa, Finland).  
 
Serum alkaline phosphatase (AP) activities were determined in the Helsinki University 
Hospital central laboratory and included the quantitation of total, bone, liver, 
intestinal, and macromolecular alkaline phosphatase activity (HUSLAB, Helsinki, 
Finland). Serum AP activities were determined using a photometric method. Alkaline 
phosphatase isoforms were quantified by performing agarose gel electrophoresis. 
Blood glucose, urinary albumin, and serum creatinine concentrations were 
determined by the Laboratory of Helsinki University Central Hospital (HUSLAB, 
Helsinki, Finland). Kidney status was determined by calculating the urinary albumin 
excretion rate (AER) and the estimated glomerular filtration rate (eGFR) using the CKD-
EPI equation169. Serum insulin concentrations were determined with the Wallac 
AutoDELFIA Insulin kit (PerkinElmer, Turku, Finland) using an automatic analyzer 
(Wallac 1235 Automatic Immunoassay System, Wallac, Turku, Finland).  
Serum triglycerides, total cholesterol, HDL cholesterol, apolipoprotein (apo) A-I, and 
apoB-100 concentrations were measured using automated enzymatic methods 
(Konelab analyzer, Thermo Scientific, Vantaa, Finland). Plasma apoB-48 
concentrations were measured by ELISA according to the manufacturer’s instructions 
(Shibayagi Co Ltd, Shibukawa, Japan). ApoE concentrations were measured by 
performing anti-apoE immunoaffinity chromatography170.  
 
4.2.2 Fecal sample measurements 
Analysis of fecal IAP activity – Study III  
Fecal IAP activity was measured by performing a colorimetric assay. Briefly, human 
(fecal) and mouse (cecum, colon) samples were homogenized and centrifuged, and 
then supernatants were collected to determine fecal IAP activities and total protein 
concentrations. A standard curve was prepared using serial dilutions of p-nitrophenyl 
phosphate (pNPP) and a fixed amount of calf intestinal alkaline phosphatase (CIAP) in 
the final reactions (Sigma). To measure the background signal, fecal extracts and all 
assay reagents were combined simultaneously into a control well before starting the 
assay. OD values were determined at 405 nm with the correction wavelength set to 
630 nm. Sample activity was calculated using the following formula: IAP activity (U/ml) 




and T is the reaction time in min). Finally, IAP activities were normalized to the fecal 
protein concentrations determined using the Lowry method (DC protein assay, 
BioRad, CA, USA). In the present study, the inter- and intra-assay coefficients of 
variation for the fecal IAP activity measurements were 13.7% and 2.5%, respectively. 
 
Analysis of fecal short chain fatty acids – Study III 
Short chain fatty acids (SCFAs) acetate [C2], propionate [C3], butyrate [C4], valerate 
[C5] and isovalerate [iC5] were measured with an HP 5890 series gas chromatograph 
(Hewlett-Packard, Waldbronn, Germany) equipped with an HP-FFAP column (30 m x 
0.53 mm; film thickness 1.0 μm) and a flame ionization detector. Briefly, fresh feces 
were diluted in water and centrifuged. A volume of 23.6 μl of 12 mM isobutyric acid 
(as an internal standard), 280 μl of 0.36 M HClO4, and 270 μl of 1 M NaOH was added 
to 50 μl of supernatant. The mixture was lyophilized, and the residue was re-dissolved 
in a mixture of 400 μl of acetone and 100 μl of 5 M formic acid. After centrifugation at 
14000 x g for 5 min at room temperature, 1 μl of supernatant was injected into the 
gas chromatograph. Standards were incorporated during all runs.  
 
Fecal antibodies – Study III 
Total secretory IgA, IgG and IgM antibodies and isotype-specific antibodies against 
oxidized LDL products (copper oxidized LDL – CuOx-LDL; malondialdehyde 
acetaldehyde LDL – MAA-LDL) were measured in fecal samples. Briefly, human (fecal) 
and mouse (cecum, colon) samples were dissolved in ice-cold PBS buffer and 
centrifuged. Supernatants were supplemented with protease inhibitors. Levels of IgA, 
IgG and IgM antibody binding to oxidized LDL were determined for the supernatants 
in a chemiluminescence immunoassay 171. Two models of oxidized LDL, CuOx-LDL and 
MAA-LDL, were used in the study 5. The amounts of bound antibody present were 
detected with alkaline phosphatase-labeled goat anti-human secondary antibodies for 
IgA, IgG and IgM (Sigma) using LumiPhos 530 chemiluminescence substrate (Lumigen). 
Luminescence was detected with a Victor3 multilabel counter, and the results are 
expressed as relative light units. Total fecal immunoglobulin levels were measured 
using a capture-sandwich chemiluminescent immunoassay171. A standard curve of 
mixed or purified human IgA, IgG or IgM was used to calculate the concentrations.  
 
 
Fecal calprotectin – Study III 
Fecal calprotectin concentrations were determined by ELISA according to the 
manufacturer’s instructions (Buhlmann, Schönenbuch, Switzerland). Fecal 
calprotectin concentrations under 50 μg/g were considered normal. Concentrations 
between 50-200 μg/g implicated increased intestinal neutrophil activity and 
inflammation. Concentrations above 200 μg/g were indicative of active inflammation 
and inflammatory bowel disease. 
4.2.3 Other measurements from human samples 
Determination of the alleles for ABO blood groups and FUT2 by PCR – Study III 
To determine ABO alleles, the following markers were examined by performing 
TaqMan real-time PCR: rs8176719, rs8176746 and rs8176747. Briefly, amplification 
reactions were carried out using 60 ng of template DNA, TaqMan® Universal Master 
Mix II (Life Technologies, Carlsbad, CA, USA) and primer (600 nM) and probe (100-300 
nM) mix (Life Technologies, Carlsbad, CA, USA) in 20-μl reaction volumes. Thermal 
cycling was performed with the following reaction conditions: denaturation at 95°C 
for 10 min followed by 40 cycles of 95°C for 3 s and 62°C for 30 s. FUT2 genotyping 
was based on the marker rs601338 and analyzed in a similar manner. The distribution 
of genotype frequencies did not deviate significantly from Hardy–Weinberg 
equilibrium. 
 
DNA isolation, PCR amplification and cloning – Study I 
Nucleic acid extraction, polymerase chain reaction (PCR), and post-PCR analysis were 
carried out in separate locations to minimize the risk of contamination. Control 
samples were run in parallel to standardize isolation and transformation procedures 
and ensure the fidelity of the procedure. 
To determine the relative prevalence of bacterial remnants in circulation, DNA was 
isolated from the sera of 14 high LPS activity patients with T1D and 10 healthy 
controls. Nucleic acids were isolated using the QIAamp DNA Mini Kit (Qiagen, Valencia, 




μg of Qiagen Carrier (poly-A carrier RNA, Qiagen) was added to each 200-μl serum 
sample. Ultrapure water was used as a negative control in the extractions.  
Previously described primers were used to PCR amplify bacterial 16S rDNA 172. Adaptor 
sequences were added to the 5’ ends of the 16S primers to facilitate annealing to the 
pBluescript KS cloning vector.  
The thermal cycler (Biometra T Professional Thermocycler, Biometra, Goettingen, 
Germany) was programmed for an initial step at 98°C for 30 s, followed by 40 thermal 
cycles of 98°C for 10 s, 55°C for 20 s and 72°C for 60 s. ExoSap-IT (Affymetrix, Santa 
Clara, CA, USA) was used to remove unincorporated primers and dNTPs according to 
the manufacturer’s recommendations. PCR products were examined in agarose gels 
stained with ethidium bromide to confirm the product size and the absence of product 
in the negative control.  
After verifying the quality, 5 μl of PCR product was incubated with 2 μl of In-Fusion 
Cloning Enhancer (Clontech, Mountaincenter View, CA, USA) for 15 min at 37°C, to 
which we added 90 ng of linearized pBluescript vector (EcoRI/BamHI), 2.8 μl of 5x 
Fusion Buffer, and 1.2 μl of Fusion Enzyme (Clontech). Ligation buffer was maintained 
at 37°C for 15-30 min, followed by 15 min at 50°C to stop the reaction.  
 
DNA isolation, PCR amplification and cloning – Study I 
Competent DH-5α cells (New England Biolabs, Ipswich, MA, USA) were transformed 
by incubating with 5 μl of 1:4 diluted ligation buffer. Transformed bacteria were 
cultured on LB agar plates containing 100 mg/ml ampicillin, 80 μg/ml 5-bromo-4-
chloro-3-indolyl β-D-galactopyranoside (X-gal), and 1 mM isopropyl thiogalactoside 
(IPTG) (Sigma–Aldrich, St. Louis, MO, USA). After overnight culture at 37°C, bacteria 
were collected, and plasmids were isolated using a QIAprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions. Plasmid clones were sequenced using a 
3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA) and BigDye v3.1 
according to the manufacturer’s instructions. The resulting sequences were analyzed 
using the Sequencher program (Gene Codes Corporation, Ann Arbor, MI, USA). 
Sequences flanking the PCR primers were blasted against microbial genomes using the 
National Center for Biotechnology Information (NCBI) database. Ten clones from each 
participant were isolated and analyzed. 
 
 
Enzyme-linked immunosorbent assays (ELISA) to detect serum antibodies against 
Pseudomonas species – Study I 
An in-house method was carried out to determine serum IgA and IgG antibody levels 
against P. aerigunosa (ATCC27835), S. maltophilia (ATCC17671) and Delftia 
acidovorans (ATCC43868), both individually and in combination. An ELISA assay was 
performed as previously described173. 
4.2.4 Murine experiments 
 
Animals 
C57BL/6 mice were purchased from Jackson Laboratories (Sacramento, CA, USA) 
Animals were maintained in accordance with the guidelines prepared by the 
Institutional Animal Care and Use Committee at Massachusetts General Hospital, 
based on the Care and Use of Laboratory Animals of the Institute of Laboratory 
Resources, National Research Council [Department of Health, Education and Human 
Services, Publication 85e23 (National Institutes of Health), revised 1985]. All animal 
protocols were reviewed with approved by the Institutional Animal Care and Use 
Committee at Massachusetts General Hospital.  
 
Animal diets 
Liquid Low-fat diet powder (LFD) [D12450HL; 70% kcal from carbohydrate, 20% kcal 
from protein, 10% kcal from fat] and a liquid high-fat diet powder (HFD) [D12451L; 
35% kcal from carbohydrate, 20% kcal from protein, 45% kcal from fat] were 
purchased from Research Diets (USA). 
 
Oral IAP supplementation in mice 
Drinking water and mouse chew diet were removed from all cages prior to beginning 
the experiments. Mice (n=28) were supplemented with liquid diet feeding bottles 
containing a suspension made of LFD powder in drinking water to acclimate mice to 
the liquid diet feeding tubes. One week later, mice were supplemented with liquid 




of IAP or its vehicle: HFD + IAP vehicle (n=4), HFD + IAP (1.5, 3.0, 7.5, 15, 30 and 60 
U/ml of liquid diet; 4 mice /treatment group) for 11 weeks. The feeding bottles were 
changed every 12 hours with fresh IAP. In the end of the experiment, IAP treated 
mice were grouped for subsequent data analysis: low IAP (1.5 and 3.0 U/ml; n=8), 
medium IAP (7.5 and 15 U/ml; n=8), high IAP (30 and 60 U/ml; n=8). 
4.2.5 Statistical methods 
Statistical differences between variables were investigated using the Spearman´s Rank 
correlation test or Pearson’s product moment correlation coefficient. Correlations 
between variables and group differences were determined with Student’s t-test, 
Kruskal-Wallis test, or Mann-Whitney U-test, when appropriate. In the animal 
experiments, the impact of oral IAP supplementation on caecal and colonic output 
measures were studied with the Jonckheere-Terpstra trend test.  A p-value ≤0.05 was 
considered significant. Statistical analyses were carried out using SPSS 15.0 (SPSS Inc., 
Chicago, USA) or the R language and environment package for statistical computing. 
4.2.5 Ethical considerations 
The research was conducted in accordance with the Declaration of Helsinki. All 
participants gave informed consent. The research was approved by the appropriate 




5.1 Study I – Systemic exposure to Pseudomonal bacteria: a potential 
link between type 1 diabetes and chronic inflammation 
5.1.1 Relative prevalence of bacterial DNA in serum 
To elucidate the origin of bacterial remnants in circulation, bacterial DNA was isolated 
from the sera of 14 high LPS activity patients with T1D and 10 healthy controls. 
With the exception of cyanobacteria, all sequences demonstrated more than 90% 
homology with the NCBI Microbial Genome database. Bacteria belonging to the genus 
cyanobacteria showed more than 80% homology with the reference sequences. 
Among 240 isolated clones, 35 unique bacterial species were identified (Table 5). Only 
5 bacterial species were found in both groups. The following bacterial phyla were the 
most prevalent: proteobacteria (73.8%), firmicutes (13.3%), actinobacteria (5.8%), 
cyanobacteria (5.0%), and bacteroides (2.1%). The majority (76%) of isolated bacterial 
clones were Gram-negative. Twenty four percent were Gram-positive.  
Over 75% of the isolated bacterial clones had genomic GC content greater than 60%. 
Approximately 23% were derived from human commensal bacterial flora. 
Approximately 11% were classified as human pathogens. Fifty-four percent 
represented environmental bacteria. Eleven percent of the identified species were 
associated with dairy processing.  
D. acidovorans (45%) and S. maltophilia (25%) were the most prevalent species. 
Notably, both belong to the Pseudomonas genus. The prevalence of S. 
maltophilia clones was significantly higher in patients with T1D compared to healthy 
controls (29.3 vs. 18.0%; p = 0.045).  
Bacterial species Gram GC (%) Type 
T1D Control ALL 
n n  n  
 % total % total % total 
Acidovorax ebreus − 67 E 0 
1 1 
1.00% 0.40% 












phytofirmans − 63 E 0 
1 1 
1.00% 0.40% 
Cyanothece sp. − 38 E 0 
10 10 
10% 4.20% 
Delftia acidovorans − 67 E 
62 46 108 
44% 46% 45% 
Flavobacteriaceae 
bacterium − 43 E 
3 1 4 
2.10% 1.00% 1.70% 
L. pneumophila str. 
Corby − 39 P 0 
1 1 
1.00% 0.40% 












petroleiphilum − 69 E 0 
1 1 
1.00% 0.40% 











maltophilia − 66 E & P 
41 18 59 
29% 18% 25% 
Xanthomonas 










phytofermentans + 35 E 0 
1 1 
1.00% 0.40% 
Clostridium sp. + 50 E 0 
2 2 
2.00% 0.80% 
Clostridium bartlettii + 29 H 0 
1 1 
1.00% 0.40% 





Enterococcus faecalis + 38 H 0 
2 2 
2.00% 0.80% 






sibiricum + 48 E 
2 1 3 
1.40% 1.00% 1.30% 
































acnes + 60 H 
1 4 5 
0.70% 4.00% 2.10% 
Staphylococcus 
haemolyticus + 33 H 0 
1 1 
1.00% 0.40% 
Staphylococcus warneri + 33 H 0 
1 1 
1.00% 0.40% 





Streptococcus sanguinis + 43 H 0 
3 3 
3.00% 1.30% 















Table 5  Bacterial clones isolated from human serum. Bacterial 
classification: E, environmental source; H, human flora; D, dairy products; P, pathogen. Note: 
percentages may not total 100% due to rounding.  
 
5.1.2 RT-PCR quantification of flagellin DNA in human PBMCs 
Real-time PCR was performed to detect flagellin from S. maltophilia and a closely 
related opportunistic pathogen, P. aeruginosa, in isolated DNA samples derived from 
peripheral blood leukocytes. Flagellin PCR was performed on 10 healthy controls and 
12 out of 14 patients with T1D included in the serum-derived bacterial DNA study, 





Primer–probe sets targeting the flagellin genes of S. maltophilia and P. aeruginosa 
were tested on DNA extracts from multiple target and off-target bacteria. The probe 
sets appeared to be specific for the target genes and demonstrated no cross-
reactivity. 
Standard curves were linear: S. maltophilia for 6.4–0.5 × 106 copies, and P. aeruginosa 
for 32–2.5 × 106 copies. The sensitivity was insufficient to produce a reliable signal in 
DNA isolated from human serum samples. However, white blood cells are able to carry 
bacterial DNA; therefore, DNA from circulating white blood cells was used.  
All samples assayed by qPCR demonstrated detectable levels of S. maltophilia and P. 
aeruginosa DNA. No differences were seen between patients and controls for S. 
maltophilia (428 ± 117 vs. 498 ± 284 copies/μg DNA; p = 0.45) or P. aeruginosa (6,152 
± 1,567 vs. 6,540 ± 2,336 copies/μg DNA; p = 0.50). Interestingly, 9 patients with T1D 
had significantly higher P. aeruginosa DNA copy numbers compared with healthy 
controls (7,762 ± 884 vs. 6,152 ± 1,567 copies/μg DNA; p = 0.035). One patient with 
T1D had an S. maltophilia copy number approximately 2.5-3.0-fold higher than the 
other subjects. When this individual was excluded from the analysis, a strong 
correlation between S. maltophilia and P. aeruginosa copy numbers (r = 0.61; p = 
0.003) was observed.  
Both S. maltophilia (n = 21; r = 0.59; p = 0.005) and P. aeruginosa (n = 22; r = 0.55; p = 
0.008) flagellin gene copy numbers significantly correlated with age. Age-related 
correlations were stronger among patients with T1D compared to healthy controls (S. 
maltophilia: n = 11; r = 0.77; p = 0.005 vs. n = 10; r = 0.29; p = 0.43; and P. aeruginosa: 
n = 12; r = 0.79; p = 0.002 vs. n = 10; r = −0.08; p = 0.83). 
 
5.1.3 Analysis of serum antibodies against Pseudomonal bacteria 
Serum IgA and IgG antibody levels against D. acidovorans, S. maltophilia, and 
P. aeruginosa were assessed to quantify systemic exposure to Pseudomonal 
bacteria. 
Within the original study cohort of 14 patients with T1D and 10 controls, we 
observed no statistically significant differences in serum IgG or IgA levels 
 
between groups. However, there was a trend towards higher IgA 
concentrations in T1D patients.  
Therefore, we assayed serum samples from 200 healthy controls and 200 
patients with T1D from the FinnDiane Study. In this larger cohort, T1D patients 
had significantly higher IgA antibody levels against Pseudomonal bacteria 




Figure 7 Serum antibody levels against Pseudomonal bacteria. 
Healthy controls (n = 200) and T1D patients (n = 200) are shown as 
triangles and circles, respectively. Da, D. acidovorans; Pa, P. 
aeruginosa; Sm, S. maltophilia; Multi, the pool of Da, Pa and Sm. Data 
shown are medians with interquartile ranges. A Mann–Whitney U test 
was implemented to determine significance. p-values within 
parentheses are adjusted for age, body mass index, and systolic blood 





Tests were adjusted for age, BMI, and systolic blood pressure. After adjustment, group 
differences in S. maltophilia and Pseudomonas-pool IgA/IgG antibody levels remained 
significant. No significant differences were observed between patients of differing 
diabetic nephropathy status.  
Correlations between CRP and antibody levels were analyzed in a subset of subjects 
(n=380). Individuals with CRP levels above 10 mg/l were excluded to minimize the 
possible influence of recent infection. All IgA antibodies correlated positively with 
serum CRP values (Table 5). In general, correlations between IgA antibodies and CRP 
were stronger in patients with T1D compared to healthy controls. No significant 
correlations were observed between serum LPS activity and IgA antibody levels (data 
not shown). However, a strong correlation was observed between serum LPS and CRP 
concentrations (r = 0.221; p < 0.001).  
 
  Serum C-reactive protein Serum C-reactive protein  (Subjects with ≤ 10 mg/l) 
  All T1D Control All T1D Control 
N 397 199 198 380 193 187 
Serum LPS 0.25* 0.22* 0.28* 0.22* 0.20* 0.27* 
Anti Da 
IgA 0.17* 0.21* 0.13 0.15* 0.19* 0.14 
Anti Pa 
IgA 0.15* 0.24* 0.04 0.16* 0.24* 0.08 
Anti Sm 
IgA 0.12* 0.13 0.11 0.11* 0.08 0.14 
Pooled 
IgA 0.15* 0.21* 0.07 0.15* 0.19* 0.1 
 
 
Table 6 Spearman rank correlation coefficients between serum C-reactive protein, LPS 
and IgA antibody levels. Da, D. acidovorans; Pa, P. aeruginosa; Sm, S. 
maltophilia; Multi, the pool of Da, Pa and Sm. * p<0.05 
5.2 Study II – High-fat meals induce systemic cytokine release without 
evidence of endotoxemia-mediated cytokine production from 
circulating monocytes and myeloid dendritic cells 
 
5.2.1 Analysis of circulating cytokines during fasting and the postprandial 
period 
 
To better understand postprandial inflammation and its link with circulating LPS, we 
gave 11 patients with T1D and 11 controls two high-fat meals: breakfast and lunch. 
From these subjects, we measured circulating cytokines, cytokine production in 
circulating cells and metabolic parameters such as HDL and triglycerides. 
A significant postprandial increase in cytokine concentrations was observed in both 
T1D patients and healthy controls. In T1D patients, we observed a significant 
postprandial increase in IL-6, TNF-α, IL-1β, IFN-α, IFN-γ, and MIP-1α levels. Controls 
showed a significant postprandial increase in IL-6, TNF-α, IL-1β, IFN-α, IL-10, and IL-12 
levels. No significant differences were observed between the two groups at either 
time point. The groups were therefore combined to increase statistical power. After 
combining, we observed significant postprandial increases in the concentrations of 8 
of the 13 innate immunity-derived cytokines: IL-6, TNF-α, IL-1β, IFN-α, IL-10, IFN-γ, IL-









Figure 8 Circulating cytokine concentrations during fasting and the postprandial period. 
Triangles and circles indicate median values for non-diabetic controls and patients with T1D, 
respectively. Values represent pg/ml of cytokine. Bars represent the interquartile range. 
Asterisks indicate a significant difference between 8:00 (fasting) and 14:00 h (postprandial) (p 
< 0.05). All analyses shown differed significantly between 8:00 and 14:00 when the patient 






Analyte T1D 8:00 T1D 14:00 p   C 8:00 C 14:00 p 
Grouped 
P 
IL-12p70 4.5 7.8 NS   12 27 0.043 0.016 
 (2.4-7.7) (5-13.2)   (3.9-23) (13-38)    
LAP 43 46 NS   49 61 NS NS 
 (21-49) (23-48)   (25-73) (29-119)    
IFN-γ 145 180 0.047   175 290 0.069 0.007 
 (63-161) (109-220)   (90-245) (176-426)    
MIP-1β 115 139 0.075   182 203 NS 0.036 
 (99-347) (118-367)   (81-570) (100-839)    
MCP-1 601 654 NS   565 583 NS NS 
 (537-682) (573-682)   (528-669) (532-678)    
IL-10 8.9 15 0.059   5 23 0.038 0.004 
 (3.8-14) (6-19.4)   (2.5-14) (11-37)    
 
MIP-1α 728 1318 0.026   2721 2236 NS NS 
 (238-1573) (399-2922)   (990-5786) (1067-5269)    
IL-8 54 98 NS   67 62 NS NS 
 (31.3-338) (45-394)   (14-474) (28-779)    
ICAM-1 352 324 NS   377 377 NS NS 
 (291-393) (293-396)   (325-461) (298-446)    
IL-6 3.4 5.7 0.012   0.7 6.3 0.018 0.001 
 (2.3-5) (2.9-7.9)   (0.2-3.8) (5.1-18)    
IL-1α 110 146 NS   201 172 NS NS 
 (23-251) (66-373)   (6-293) (12-369)    
IFN-α 23 25 0.003   21 25 0.008 0 
 (21-24) (23-26)   (21-23) (24-28)    
IL-13 142 199 0.063   142 252 0.021 0.003 
 (112-189) (125-225)   (113-182) (186-380)    
IP-10 56 57 NS   73 92.8 NS NS 
 (46-65) (52-67)   (55-107) (65-125)    
IL-4 57 69 NS   55 84 NS 0.039 
 (37-69) (45-73)   (29-89) (65-109)    
IL-17A 79 90 0.022   119 210 0.036 0.003 
 (22-96) (41-104)   (37-229) (155-328)    
IL-1β 131 204 0.011   119 232 0.063 0.001 
 (78-166) (141-213)   (46-232) (160-297)    
TNF-α 42 75 0.017   31 70 0.046 0.002 
 (26-58) (41-87)   (21-40) (56-94)    
E-Selectin 86 106 NS    159 132 NS NS 
  (59-122) (64-161)     (76-258) (69-302)     
 
Table 7 Medians and interquartile ranges of circulating cytokines. Values represent 
the median pg/ml of cytokine. Interquartile ranges are in parentheses. p-values 
represent 8:00 vs. 14:00 within-group p values. Group p values represent 8:00 vs. 






Interestingly, serum LPS activity levels and circulating cytokine concentrations were 
not significantly correlated. Postprandial plasma triglycerides showed a significant 
positive association with circulating IL-12 (r=0.574, p=0.013) and IL-10 (r=0.491, 
p=0.028) concentrations. Postprandial HDL cholesterol concentrations were inversely 
associated with circulating IP-10 (r=-0.519, p=0.016) and IL-10 (r=-0.449, p=0.030). 
 
 
5.2.2 Flow cytometric analysis of IL-6, TNF-α, and IL-1β cytokine production 
in unstimulated blood monocytes and dendritic cells  
 
To assay inflammation in resting cells during fasting and the postprandial 
period, we measured the production of three cytokines (IL-6, TNF-α, and IL-1β) 
in CD14-positive monocytes and CD1c-positive mDCs before and after a series 
of high-fat meals. These samples, which lacked in vitro exogenous LPS 
stimulation, were designated baseline samples. No significant group 
differences were observed for fasting baseline monocyte TNF-α, IL-6, and IL-1β 
production (Figure 9). Diabetic monocytes exhibited lower IL-6 expression 
compared to healthy controls in postprandial baseline samples (8 vs. 10% 
expressing, p=0.008). Fasting mDCs from patients with T1D exhibited higher 
levels of TNF-α (11 vs. 5% expressing, p=0.01) and IL-1β (9 vs. 6% expressing, 
p=0.02) compared to non-diabetic controls (Figure 8). 
 
5.2.3 Flow cytometric analysis of IL-6, TNF-α, and IL-1β cytokine production 
in LPS-stimulated blood monocytes and dendritic cells  
To assay responsiveness to bacterial endotoxin stimulation during fasting and 
the postprandial period, we measured the production of three cytokines (IL-6, 
TNF-α, and IL-1β) in CD14+ monocytes and CD1c+ mDCs after stimulation with 
100 ng/ml E. coli LPS.  
No significant differences were observed between T1D patients and healthy 
controls for LPS-induced monocyte cytokine production either during fasting 
 
or the postprandial period. During fasting, LPS-stimulated mDCs from patients 
with T1D exhibited significantly elevated IL-6 (p=0.034) and IL-1β (p=0.040) 
production compared to healthy controls (Figure 9).  
Interestingly, no group differences in cytokine production were observed in 
postprandial LPS-stimulated mDCs (Figure 9, Table 7). HbA1c negatively 
correlated with fasting IL-6 and postprandial TNF-α (r=-0.620, p=0.042; and -























Figure 9  Cytokine secretion during fasting and the postprandial period. 
Values represent the median percent of cells expressing the indicated cytokine. Sub 
indicates the subject type, triangles are controls and circles are T1D patients. Bars 




5.3 Study III – Patients with type 1 diabetes exhibit signs of intestinal 
inflammation 
 
5.3.1 Patient Data 
To elucidate intestinal inflammation and IAP, fecal samples were studied to 
determine the levels of fIAP, calprotectin, immunoglobulins, and SCFAs in 41 
non-diabetic controls, 36 patients with type 1 diabetes and normal albumin 
excretion (AER<20 μg/min or <30 mg/24 h), and 10 patients with type 1 
diabetes and macroalbuminuria (AER≥200 μg/min or ≥300 μg/24 h).  
The focus of Study III was to investigate intestinal and circulating lipids and 
inflammation; therefore, participants were analyzed for baseline differences in 
gender, BMI, lipid profiles, age and diet. No group differences were observed 
in terms of gender, BMI or circulating lipid profiles. Patients with T1D were 
slightly older than non-diabetic controls. Patients with macroalbuminuria had 
higher systolic blood pressure than patients with a normal AER or healthy 
controls.  
No differences were observed between the groups in terms of either pre-study 
energy intake (control: 2015±517 kcal/24 h; T1D normal AER: 2085±721 
kcal/24 h; T1D macroalbuminuria: 1743±640 kcal/24 h) or the percent energy 
derived from dietary fats (control: 38%; T1D normal AER: 41%; T1D 
macroalbuminuria: 38%). Energy intake during the 10-h study day was 2600 
kcal, of which 50% came from fats. 
The primary comparisons investigated in Study III are 1) patients with T1D and normal 
AER vs non-diabetic controls, and 2) patients with T1D and normal AER vs patients 
with T1D and macroalbuminuria.  
5.3.2 Measurements from fecal samples 
Patients with T1D and normal AER had lower levels of fecal intestinal-AP (fIAP) 
compared with controls (61 [26-221] vs. 131 [73-837] U/l, p=0.01). No correlations 
between fIAP activity and serum LPS activity, serum lipids, or CRP levels were 




concentrations of three of the five short-chain fatty acids (SCFAs) studied. Propionate 
(70 [33-106] vs. 91 [66-116] μmol/g dry weight; p=0.015) and butyrate (39 [23-81] vs. 
71 [40-101] μmol/g dry weight, p=0.020) were significantly reduced compared to 
controls (Figure 10). Moreover, patients with T1D had lower total SCFA levels (414 
[234-638] vs. 496 [404-720] mmol/g dry weight, p=0.043), although this was likely 
driven by propionate, butyrate and valerate. SCFA concentrations were positively 
associated with carbohydrate intake in normoalbuminuric patients (r=0.483, 
p=0.003). 
 
Figure 10  Fecal short-chain fatty acids (SCFA). Total SCFA, propionate, and butyrate levels 
were lower in patients with T1D and normal AER compared to controls. White boxes: controls; 
gray boxes: patients with T1D and normal AER; dark gray boxes: patients with T1D and 
macroalbuminuria. Values are shown as natural logs of the SCFA concentration in μmol per 
gram. * p<0.05. 
 
 
Fecal calprotectin is a stable neutrophil-derived biomarker for inflammatory bowel 
disease (IBD) and has been used in a large number of IBD diagnostic studies174. 
Normoalbuminuric patients have elevated fecal calprotectin levels compared to 
controls (48 [29-90] vs. 29 [16-59] μg/g, p=0.028) (Figure 11). We designated values 
greater than 50 μg/g as representing an inflamed gut174. Normoalbuminuric patients 
with T1D were more likely to have gut inflammation than healthy controls (50% vs. 
25%, p=0.024). Calprotectin was further elevated in macroalbuminuric patients. Forty 
percent of macroalbuminuric patients met the clinical criteria for IBD diagnosis: fecal 




patients with T1D and normal AER compared to controls. White boxes: controls; gray boxes 
patients with T1D and normal AER; dark gray boxes: patients with T1D and macroalbuminuria. 
Values are shown as natural logs of the SCFA concentration in μmol per gram. * p<0.05. 
62 





Indirect ELISA assays were performed to measure total IgA, IgG and IgM levels as well 
as specific IgA antibodies generated against copper-oxidized LDL or malondialdehyde- 
(MAA)-modified LDL in fecal extracts. Normoalbuminuric patients demonstrated 
reduced levels of total IgA and anti-oxLDL compared to controls (total IgA 1.9 [0.7-3.6] 
vs. 3.4 [1.5-6.9] μg/g wet weight, p=0.015; IgA-MAA 9.2 [3.8-28.8] vs. 24.4 [12.7-57.1] 
RU, p=0.008; IgA-CuOx 22.1 [12.0-43.4] vs. 56.4 [23.8-112.1] RU, p=0.002). IgG and 
IgM were similar between both groups. Fecal IAP correlated with total IgA, IgG and 
IgM levels across groups (correlation determined using all subjects: IgA vs. fIAP 
r=0.266, p=0.039; IgG vs. fIAP r=0.349, p=0.001; and IgM vs. fIAP r=0.432, p<0.001).  
  
Oral IAP supplementation in mice 
C57BL/6 mice were exposed to high-fat diet and various doses (low 1.5-3.0 U ml-1, 
medium 7.5-15 U ml-1, high 30-60 U ml-1) of calf intestinal phosphatase (cIAP) for 11 
weeks, where after caecal and colonic samples were isolated and extracted for sub-
sequent analyses (Figure 12). Compared to the reference group (no_cIAP; n=4), mice 
receiving the highest oral doses of IAP (high_cIAP; n=8) showed the highest caecal 
(7.9-fold; 411±106 vs. 3246±694 U/l, p=0.003) and colonic (9.8-fold; 378±234 vs. 
3709±1096 U/l, p=0.003) IAP activity.  
Oral IAP supplementation increased the caecal (9.3-fold; 4.8±2.2 vs. 44.5±15.0 μg/ml, 
p=0.003) and the colonic (3.1-fold; 5.9±2.6 vs. 18.5±9.7 μg/ml, p=0.014) content of 
total IgA, whereas total IgG and total IgM levels were unaffected. IAP activity levels 
correlated with the caecal (r=0.82, p<0.001) and the colonic (r=0.67, p<0.001) content 





C57BL/6 (n=28) mice were exposed to high-fat diet and various doses of cIAP: no cIAP (n=4), 
low cIAP dose 1.5-3.0 U/ml (n=8), medium cIAP dose 7.5-15 U/ml (n=8), high cIAP dose 30-60 
U/ml (n=8) for 11 weeks. IAP activity and total IgA levels are shown for caecal and colonic 
samples. Histogram data is presented as mean ± standard error of mean. Shown p-values are 
obtained from the Jonckheere-Terpstra trend test. * p<0.01, ** p<0.001. 
 
5.3.3 Serum sample measurements 
 
Serum Alkaline Phosphatases 
Alkaline phosphatase was quantified every 2 h during the investigation day. No group 
differences were observed for total alkaline phosphatase activity. Total alkaline 
phosphatase (total-AP) positively correlated with CRP in controls (r=0.455, p=0.006) 
and normoalbuminuric patients (r=0.366, p=0.036). Total-AP and triglycerides also 
correlated in normoalbuminuric patients (r=0.399; p= 0.021). These associations were 
driven by the liver isoform, which accounted for nearly 50% of all alkaline phosphatase 
in circulation. Liver alkaline phosphatase correlated with CRP (control r=0.460, 
p=0.003; normoalbuminuric T1D r=0.364, 0.037) and triglycerides (normoalbuminuric 
T1D r=0.472, p=0.006). To assess the daily accumulation of serum factors, the area 
under the curve (AUC) was calculated for each patient and for each analyte based on 
measurements from the six samples taken during the day. 
An analysis of alkaline phosphatase isoforms found no changes in bone, liver, or macro 
isoforms over the course of the investigation day. Interestingly, intestinal isoform 
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(sIAP) levels showed a significant postprandial increase (Figure 13). At all time points 
and over the course of the day (AUC), normoalbuminuric patients exhibited elevated 
levels of sIAP compared to controls (Figure 13, AUC 87.7 [17.9-202.2] vs. 21.6 [8.1-
85.2]; p=0.007). ABO blood group and FUT2 secretory phenotype frequencies were 
similar between groups, and the difference in sIAP remained significant after 
controlling for these factors. These frequencies were tested due to the role of blood 
groups and the FUT2 genotype in IAP production and secretion. In controls, sIAP-AUC 
was negatively associated with postprandial endotoxemia (LPS-AUC r=-0.454, 
p=0.005) and positively associated with HDL-lipoprotein metabolites (HDL-
cholesterol-AUC r=0.404, p=0.011; ApoA1-AUC r=0.422, p=0.007; CETP-AUC r=0.464, 
p=0.003). Fecal IAP showed no association with sIAP at any time point or with sIAP-
AUC. 
Macroalbuminuric patients demonstrated elevated levels of the liver isoform during 
fasting compared to normoalbuminuric patients (36 [31-46] vs. 27 [16-35], p=0.041), 
and this elevation continued throughout the day (AUC 330 [273-408] vs. 214 [150-
301], p=0.013). In normoalbuminuric patients, fasting liver-AP activity was strongly 
associated with obesity (BMI r=0.541, p=0.001), triglycerides (r=0.472, p=0.006) and 
percent body fat (r=0.449, p=0.009). No group differences were observed for total-AP, 
likely driven by the lack of variance in the bone isoform, which represents nearly 50% 




Figure 13 ne phosphatase activity 
(sIAP). Patients with T1D and normal AER had elevated serum IAP levels compared to controls. 
Meals were given at 8:00, 12:00, and 16:00. White boxes: controls; gray boxes: patients with 









LPS and methylated CpG DNA are two bacterial remnants that are recognized by the 
human innate immune system. Upon ligation of these bacterial remnants, human cells 
release inflammatory mediators, which in turn contribute to the development of 
many diseases, such as atherosclerosis, as well as diabetic complications.  
The presence of elevated levels of bacterial remnants such as LPS in patients with T1D 
has become evident, but the source and consequences have not been well 
characterized7. Determining the bacterial species and strains that give rise to the LPS 
that is detected by the LAL assay would facilitate a better understanding of the LPS 
source and the development of therapeutics or lifestyle interventions to decrease the 
amount of active LPS in circulation. The most likely sources for the LPS that is 
commonly observed in circulation include the oral cavity and gut.  
Studies I, II and III were performed to better understand the role of circulating 
bacterial components and their potential associations with inflammatory responses 
in type 1 diabetes.  
6.1 Identification of bacterial DNA – clues regarding the source of bacterial 
remnants 
Data from both serum-derived bacterial DNA and serum antibodies has demonstrated 
patients with T1D experience increased exposure to or infections with Pseudomonal 
bacteria compared with the general population (Study I).  
The driving force behind the identification of bacterial DNA in circulation is the desire 
to elucidate the possible routes of entry for circulating LPS, based on the hypothesis 
that isolated DNA enters the bloodstream together with LPS.  
One potential route of entry for circulating bacterial remnants is the intestinal tract. 
Patients with T1D have altered intestinal barrier function, which may lead to increased 
gut permeability175. As shown in Study I, a significant proportion of the identified DNA 
was actually derived from environmental bacteria and pathogens. Therefore, it is 
highly unlikely that circulating bacterial DNA is derived from the intestine given that 
less than 2% of all identified bacterial species are gastrointestinal tract-specific. These 
 
data align with another study in which healthy subjects were found to have only trace 
amounts of bacterial DNA derived from gut bacteria176. 
The second potential route of entry for bacterial remnants into circulation is the oral 
cavity. Indeed, patients with T1D suffer from an increased rate of periodontitis107. 
Moreover, in the general population, chewing, tooth brushing and other dental 
procedures cause bacteremia and endotoxemia108,177,178, suggesting that the bacterial 
DNA found in circulation does not come from the gastrointestinal tract but rather an 
alternative route of entry.  
The most prevalent bacteria were of Pseudomonal origin, which belongs to the 
phylum proteobacteria. Notably, patients with T1D had significantly higher 
frequencies of S. maltophilia (a Pseudomonal bacteria) clones in their serum 
compared to healthy controls. The overrepresentation of proteobacteria may be 
attributable to the overrepresentation of proteobacterial colonization or infections. 
Interestingly, some of the identified bacteria are involved in oral infections, which 
cause bleeding gums and thereby may increase the amount of bacterial remnants in 
circulation179,180. 
However, differences in prevalence may also be related to differences in host 
clearance mechanisms or increased resistance to proteolytic degradation based on 
bacterial or DNA structure within that phylum. Interestingly, immune deficiencies 
leading to an impaired response to proteobacteria have previously been shown to 
cause intestinal inflammation in animal models 181, a phenomenon that is more 
common in patients with T1D according to Study III.  
However, there was no correlation between LPS activity and either bacterial DNA 
composition or antibodies against identified bacterial species, casting doubt on the 
hypothesis of shared entry; however, this phenomenon may also be attributable to 
differences in clearance mechanisms and half-lives. Indeed, it is entirely plausible that 
bacterial LPS enters circulation through mechanisms unrelated to the origin of 




6.2 High-fat diets: a framework for investigating the origins and 
consequences of acute postprandial endotoxemia and inflammation 
Multiple high-fat meals were given to 52 patients with T1D and 41 healthy controls to 
investigate the effects of dietary fat on intestinal inflammation, postprandial 
endotoxemia and its subsequent systemic inflammation in the context of T1D. Fecal 
samples were collected before and after the exam, and blood samples were taken 
every 2 h from 8:00 until 18:00. A number of studies were then conducted on the 
whole cohort and cohort subgroupings. Studies II and III in this thesis are among the 
studies conducted on the high-fat diet cohort.  
According to earlier studies, fatty diets trigger metabolic endotoxemia and systemic 
inflammation11,138. Although the precise mechanisms of this postprandial 
endotoxemia and inflammation are not clear, it has been suggested that increased 
chylomicron production triggered in response to a high-fat diet increases LPS 
transport from the gut into circulation10,139,140. Given the established link between the 
progression of diabetic kidney disease and elevated levels of endotoxins and 
inflammatory markers, the pro-inflammatory response to dietary fat may play a role 
in the pathogenesis and progression of diabetic complications3-5,7,182. Moreover, these 
factors likely become pathogenic if anti-inflammatory counter-regulatory mechanisms 
fail. Indeed, in vitro experiments in isolated cells have found increased TLR4 
expression and responsiveness in cells from patients with T1D61,78,183.  
In Study II, we sought to investigate cellular cytokine secretion in postprandial 
immune cells to elucidate the cellular origins of postprandial inflammation and 
confirm the dysregulation of LPS reactivity of diabetic immune cells in an ex vivo 
setting.  
Our ex vivo stimulation tests in whole blood were unable to confirm reports of 
increased monocyte cytokine secretion in response to LPS. One potential reason for 
this is the presence of different amounts of autologous serum factors such as LPS-
binding proteins or serum lipids in the peripheral blood of patients with T1D. Indeed, 
patients with T1D had elevated fasting serum HDL cholesterol levels, which are known 
to buffer LPS-induced inflammation184. However, our data did not suggest any effects 
of serum HDL cholesterol on cytokine production in circulating innate immune cells. 
 
The experimental design employed in the fat tolerance study facilitated the 
investigation of systemic and intracellular inflammation to elucidate the mechanisms 
of postprandial endotoxemia and inflammation. Study II found that acute, high-fat 
meals increase circulating cytokines but have no effect on serum LPS activity levels or 
cytokine production in circulating immune cells. Thus, high-fat meals increase 
circulating cytokines and chemokines independent of postprandial LPS and circulating 
innate immune cells. Therefore, postprandial inflammation is likely regulated at the 
tissue level in response to fats or locally accumulated endotoxins. Indeed, evidence 
from murine models has suggested that postprandial inflammation may be derived 
from the intestine, liver or adipose tissue 185,186.  
Interestingly, unlike previous studies using isolated cells, study II found no difference 
in the LPS responsiveness of circulating cells in whole blood from patients with T1D 
compared to controls. This discrepancy with previous reports may be attributable to 
endogenous factors within the blood that buffer the hyperresponsiveness observed 
in cells isolated from patients with T1D. 
6.3 High-fat diets: a framework for investigating intestinal homeostasis and 
metabolic disturbances in type 1 diabetes 
The high-fat diet trial resulted in a study that was used for several projects. The first 
study, utilizing most of the participants, found that controls showed only a modest 
increase in postprandial LPS activity. However, patients with T1D experienced only a 
modest decrease in LPS activity in response to multiple fatty meals14. This is in contrast 
with earlier, smaller studies in humans reporting increased postprandial LPS 
activity11,138. The discrepancy with previous studies may be attributable to the effects 
of postprandial lipemia in the LAL assay. In our studies, we corrected for the distorting 
effects of serum triglycerides by subtracting the sample background from the 
absorption. The uncorrected lipemic solutions yielded higher perceived activity levels 
than non-lipemic solutions. Therefore, it is possible that earlier reports on 
postprandial endotoxemia were artefactual, primarily driven by lipid-induced 
nonspecific signals.  
Lassenius187 (2012) reported increases in postprandial inflammation despite the lack 




serum LPS activity levels during the day and the inflammatory markers IL-6, SAA, CRP 
or sCD14. This agrees with Study II and further underscores the decoupled nature of 
postprandial LPS and concomitant inflammation. Therefore, it is likely that 
postprandial LPS exhibits attenuated toxicity. This could be the result of LPS-
detoxifying factors such as alkaline phosphatases or the lipolysis-induced postprandial 
generation of HDL. Study III, therefore, investigated intestinal inflammation and 
alkaline phosphatase, which are factors that might contribute to systemic 
inflammation, LPS internalization, and LPS toxicity.  
Study III reported inflammation in the intestine in patients with both uncomplicated 
and complicated T1D. All patients with T1D showed significantly elevated calprotectin 
levels, and 40% of the patients with diabetic nephropathy had levels above the 
diagnostic threshold for inflammatory bowel disease.  
Calprotectin is a neutrophil-derived factor that has been used both for the diagnosis 
of inflammatory bowel disease and to distinguish between inflammatory and 
functional bowel disorders188,189. It has previously been shown that elevated levels of 
fecal calprotectin reflect neutrophil migration to the intestinal lumen190. In a separate 
study using the same participants, patients with T1D exhibited a blunted increase in 
circulating neutrophils in response to high-fat meals14. Taken together, the elevated 
calprotectin levels and blunted neutrophil response suggest that patients with 
diabetes have an inflamed intestine with neutrophil infiltration. However, further 
studies are needed to clarify the role of neutrophils in intestinal inflammation in T1D.  
Intestinal inflammation was further evidenced by diminished levels of fecal IAP in stool 
samples from patients with T1D. This also agrees with previous reports demonstrating 
decreased fecal IAP in the stool samples of patients with inflammatory bowel disease 
and celiac disease161,191. Given the role that IAP plays in the detoxification of LPS, it is 
possible that gut-derived bacterial LPS from patients with T1D is more toxic. The LPS-
detoxifying role of IAP and other alkaline phosphatases may explain the seemingly 
reduced inflammatory capacity of LPS observed in Study II.  
The prevalence of inflammatory bowel disease in patients with T1D is a growing area 
of interest, and one recent study found the prevalence of inflammatory bowel disease 
to be 6-fold higher in patients with T1D compared to the general population152. 
Notably, our data suggest that the similarities with clinical inflammatory bowel 
 
disease extend well beyond fecal calprotectin. Indeed, our data show lower fecal IAP 
activity, lower levels of butyrate and reduced overall concentrations of short-chain 
fatty acids. These results align with what has been observed in inflammatory bowel 
disease and further suggest that the intestine plays an integral role in inflammation in 
the context of T1D160,192,193. Furthermore, the heightened inflammatory state coupled 
with a more permeable gut might contribute to increased translocation of 
inflammatory mediators from the gut into circulation.  
In contrast to what was observed in fecal samples, patients with T1D were found to 
have aberrantly high levels of circulating IAP. While IAP is released directly into 
circulation by the enterocytes, it also enter circulation via increased gut permeability 
caused by intestinal inflammation153,155,194. Alternatively, the release of IAP into 
circulation may be part of a compensatory mechanism intended to resolve ongoing 
endotoxin-mediated inflammation. Indeed, serum IAP activity levels were associated 







7 Summary and Conclusions 
 
The present studies concentrated on endogenous and exogenous factors that 
influence inflammation, which represents an important step in the development of 
diabetic kidney disease. The investigated factors were bacterial LPS and DNA, the 
postprandial milieu, and markers of intestinal inflammation and homeostasis.  
7.1 Study I  
In Study I, the proportion of isolated DNA in T1D patients significantly differed from 
that of healthy controls, and this was reflected in a multistereotype antibody analysis. 
Moreover, we reported an overrepresentation of pathogenic and environmental flora 
with a near absence of normal intestinal flora. Further investigation into the most 
prevalent flora revealed them to be involved in oral infections, raising the possibility 
that bacterial DNA enters into circulation through the oral cavity. Specifically, oral 
infections may cause bleeding gums and thereby allow more bacterial components to 
enter into circulation. Notably, no correlation was observed between LPS activity and 
either bacterial DNA composition or antibodies against identified bacterial species. It 
is therefore plausible that the entry mechanisms and points of entry of LPS and 
bacterial DNA are different.  
These observations build on the body of knowledge regarding immunological 
dysregulation and differential infection rates and outcomes in patients with T1D. 
7.2 Study II  
Study II was the first study to focus on the effects of multiple physiological high-fat 
meals on cytokine production in circulating innate immune cells. Furthermore, it was 
the first to investigate postprandial inflammation and cellular activation in the context 
of T1D. Multiple high-fat meals increased circulating cytokines and chemokines 
independent of postprandial LPS. Moreover, this increase was not mediated by 
circulating innate immune cells. Therefore, postprandial inflammation is not induced 
by increased amounts of systemic LPS and is likely indicative of diet-induced, tissue-
specific inflammation. Based on these results, postprandial inflammation may derive 
 
from intestine, liver or adipose tissue inflammation. Study II represents a paradigm 
shift in our understanding of early postprandial inflammation and has sparked further 
studies into the source and mechanisms of postprandial inflammation. 
7.3 Study III 
In Study III, patients with T1D demonstrated significantly elevated levels of 
calprotectin coupled with aberrantly low levels of fecal IAP activity as well as butyrate 
and overall short-chain fatty acid concentrations. Taken together, these data point to 
a general state of intestinal inflammation in patients with T1D. Gut inflammation 
explains the commonly observed postprandial systemic inflammation through the 
release of inflammatory mediators into circulation. Study III also highlighted the 
overlap of T1D with inflammatory bowel disease, with even higher intestinal 
inflammation found in macroalbuminuric patients with T1D. Importantly, the results 
in Study III suggest that oral IAP or butyrate supplementation may suppress low-grade 
intestinal inflammation in patients with diabetes. Further studies are needed to better 
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